WO2012035421A2 - Pyridine compounds and the uses thereof - Google Patents
Pyridine compounds and the uses thereof Download PDFInfo
- Publication number
- WO2012035421A2 WO2012035421A2 PCT/IB2011/002172 IB2011002172W WO2012035421A2 WO 2012035421 A2 WO2012035421 A2 WO 2012035421A2 IB 2011002172 W IB2011002172 W IB 2011002172W WO 2012035421 A2 WO2012035421 A2 WO 2012035421A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- optionally substituted
- compound
- alkyl
- fluorophenoxy
- Prior art date
Links
- 0 CCC1C*CC1 Chemical compound CCC1C*CC1 0.000 description 16
- DJBJFELFNRFNLC-ROLXFIACSA-N CC(C)[C@@H]1OC1N Chemical compound CC(C)[C@@H]1OC1N DJBJFELFNRFNLC-ROLXFIACSA-N 0.000 description 1
- SYXICYJMBZMVKA-UHFFFAOYSA-N CC1(C)OB(c2cccc(Oc(cc3)ccc3F)c2)OC1(C)C Chemical compound CC1(C)OB(c2cccc(Oc(cc3)ccc3F)c2)OC1(C)C SYXICYJMBZMVKA-UHFFFAOYSA-N 0.000 description 1
- GMWOIURKQPTGNF-UHFFFAOYSA-N CCCN(CCN1)C1=O Chemical compound CCCN(CCN1)C1=O GMWOIURKQPTGNF-UHFFFAOYSA-N 0.000 description 1
- IYVYLVCVXXCYRI-UHFFFAOYSA-N CCC[n]1cncc1 Chemical compound CCC[n]1cncc1 IYVYLVCVXXCYRI-UHFFFAOYSA-N 0.000 description 1
- HIAUUKLDIXZXKP-UHFFFAOYSA-N CCOC(c1cc(Cl)cc(-c2cc(Oc(cc3)ccc3F)ccc2)n1)=O Chemical compound CCOC(c1cc(Cl)cc(-c2cc(Oc(cc3)ccc3F)ccc2)n1)=O HIAUUKLDIXZXKP-UHFFFAOYSA-N 0.000 description 1
- BKDVLXYPBAYFMR-UHFFFAOYSA-N CCOC(c1cc(Cl)cc(Cl)n1)=O Chemical compound CCOC(c1cc(Cl)cc(Cl)n1)=O BKDVLXYPBAYFMR-UHFFFAOYSA-N 0.000 description 1
- CJLQZBBQDNYGCJ-UHFFFAOYSA-N CN(c1ccccc1)c1nc(C(O)=O)cc(-c(cc2)ccc2Oc(cc2)ccc2F)c1 Chemical compound CN(c1ccccc1)c1nc(C(O)=O)cc(-c(cc2)ccc2Oc(cc2)ccc2F)c1 CJLQZBBQDNYGCJ-UHFFFAOYSA-N 0.000 description 1
- YBTFTGFYYGLNEQ-UHFFFAOYSA-N COCCOCCOCCOCCOCCOCCOCCOCc1nc(-c(cc2)ccc2Oc2ccc(C(F)(F)F)cc2)ccc1 Chemical compound COCCOCCOCCOCCOCCOCCOCCOCc1nc(-c(cc2)ccc2Oc2ccc(C(F)(F)F)cc2)ccc1 YBTFTGFYYGLNEQ-UHFFFAOYSA-N 0.000 description 1
- RDQBVBSJPFZMMM-YEJXKQKISA-N C[C@@H](C(N)=O)Nc1cc(-c(cc2)ccc2Oc(cc2)ccc2F)nc([C@@H](CO)O)c1 Chemical compound C[C@@H](C(N)=O)Nc1cc(-c(cc2)ccc2Oc(cc2)ccc2F)nc([C@@H](CO)O)c1 RDQBVBSJPFZMMM-YEJXKQKISA-N 0.000 description 1
- ZDJLHRTWFNZVBB-INIZCTEOSA-N N#Cc1cc(Oc(cc2)ccc2-c2nc(C(NC[C@@H](CO)O)=O)ccc2)ccc1C(F)(F)F Chemical compound N#Cc1cc(Oc(cc2)ccc2-c2nc(C(NC[C@@H](CO)O)=O)ccc2)ccc1C(F)(F)F ZDJLHRTWFNZVBB-INIZCTEOSA-N 0.000 description 1
- OZQKIFQKNMBKAN-FQEVSTJZSA-N N#Cc1nc(-c(cc2)ccc2Oc(cc2)ccc2F)cc([C@H](CO)O)c1 Chemical compound N#Cc1nc(-c(cc2)ccc2Oc(cc2)ccc2F)cc([C@H](CO)O)c1 OZQKIFQKNMBKAN-FQEVSTJZSA-N 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N NC(Oc1ccccc1)=O Chemical compound NC(Oc1ccccc1)=O BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- YOJVMCGWBVPSQK-UHFFFAOYSA-N NC(c1cc(C2=CCNCC2)cc(-c(cc2)ccc2Oc(cc2)ccc2F)n1)=O Chemical compound NC(c1cc(C2=CCNCC2)cc(-c(cc2)ccc2Oc(cc2)ccc2F)n1)=O YOJVMCGWBVPSQK-UHFFFAOYSA-N 0.000 description 1
- ZLIVQXBWKHHDTN-UHFFFAOYSA-N NC(c1cc(N(CC2)CCN2C(N)=O)cc(-c(cc2)ccc2Oc(cc2)ccc2F)n1)=O Chemical compound NC(c1cc(N(CC2)CCN2C(N)=O)cc(-c(cc2)ccc2Oc(cc2)ccc2F)n1)=O ZLIVQXBWKHHDTN-UHFFFAOYSA-N 0.000 description 1
- PPCFKJMLAXIIOE-UHFFFAOYSA-N NC(c1cc(N2CCNCC2)cc(-c(cc2)ccc2Oc(cc2)ccc2F)n1)=O Chemical compound NC(c1cc(N2CCNCC2)cc(-c(cc2)ccc2Oc(cc2)ccc2F)n1)=O PPCFKJMLAXIIOE-UHFFFAOYSA-N 0.000 description 1
- OYKHEVOCICOORG-UHFFFAOYSA-N NC(c1cc(NCc2cccnc2)cc(-c(cc2)ccc2Oc(cc2)ccc2F)n1)=O Chemical compound NC(c1cc(NCc2cccnc2)cc(-c(cc2)ccc2Oc(cc2)ccc2F)n1)=O OYKHEVOCICOORG-UHFFFAOYSA-N 0.000 description 1
- HFIOGKRKJRAZJQ-INIZCTEOSA-N NC(c1nc(-c(cc2)ccc2Oc(cc2)ccc2F)cc(C[C@@H](CO)O)c1)=O Chemical compound NC(c1nc(-c(cc2)ccc2Oc(cc2)ccc2F)cc(C[C@@H](CO)O)c1)=O HFIOGKRKJRAZJQ-INIZCTEOSA-N 0.000 description 1
- OJMKHKHJCBSJQE-UHFFFAOYSA-N NC(c1nc(-c(cc2)ccc2Oc(cc2)ccc2F)cc(NCc2ccncc2)c1)=O Chemical compound NC(c1nc(-c(cc2)ccc2Oc(cc2)ccc2F)cc(NCc2ccncc2)c1)=O OJMKHKHJCBSJQE-UHFFFAOYSA-N 0.000 description 1
- PGBOYPRNYSGJIE-LJQANCHMSA-N OC[C@H](c1nc(-c(cc2)ccc2S(Nc(cc2)ccc2F)(=O)=O)ccc1)O Chemical compound OC[C@H](c1nc(-c(cc2)ccc2S(Nc(cc2)ccc2F)(=O)=O)ccc1)O PGBOYPRNYSGJIE-LJQANCHMSA-N 0.000 description 1
- IRRJAIYAFQIPNB-UHFFFAOYSA-N OCc1cccc(-c(cc2)ccc2Oc2ccc(C(F)(F)F)cc2)n1 Chemical compound OCc1cccc(-c(cc2)ccc2Oc2ccc(C(F)(F)F)cc2)n1 IRRJAIYAFQIPNB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/58—Amidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Definitions
- This invention is in the field of medicinal chemistry.
- the invention relates to novel substituted pyridine compounds and the use of these compounds as blockers of voltage-gated sodium (Na + ) channels.
- VGSCs Voltage-gated sodium channels
- CNS central nervous system
- PNS peripheral nervous system
- sodium channels are primarily responsible for generating the rapid upstroke of the action potential.
- sodium channels are essential to the initiation and propagation of electrical signals in the nervous system.
- Proper function of sodium channels is therefore necessary for normal function of the neuron. Consequently, aberrant sodium channel function is thought to underlie a variety of medical disorders (See
- VGSCs are composed of one a-subunit, which forms the core of the channel and is responsible for voltage-dependent gating and ion permeation, and several auxiliary ⁇ -subunits (see, e.g., Chahine et al, CNS & Neurological Disorders-Drug Targets 7:144-158 (2008) and Kyle and Ilyin, J. Med. Chem. 50:2583-2588 (2007)).
- a-Subunits are large proteins composed of four homologous domains. Each domain contains six a-helical transmembrane spanning segments.
- Names for this family include SCNx, SCNAx, and Na v x.x (see Table 1, below).
- the VGSC family has been phylogenetically divided into two subfamilies Na v l.x (all but SCN6A) and Na v 2.x (SCN6A).
- the Na v l.x subfamily can be functionally subdivided into two groups, those which are sensitive to blocking by tetrodotoxin (TTX-sensitive or TTX-s) and those which are resistant to blocking by tetrodotoxin (TTX-resistant or TTX-r).
- the SCN5A gene product (Na v 1.5, HI) is almost exclusively expressed in cardiac tissue and has been shown to underlie a variety of cardiac arrhythmias and other conduction disorders (Liu et al., Am. J. Pharmacogenomics 5:173-179 (2003)). Consequently, blockers of Na v 1.5 have found clinical utility in treatment of such disorders (Srivatsa et al. , Curr. Cardiol. Rep. 4:401-410 (2002)).
- TTX-resistant sodium channels Na v 1.8 (SCN10A, PN3, SNS) and Na v 1.9 (SCN11A, NaN, SNS2) are expressed in the peripheral nervous system and show preferential expression in primary nociceptive neurons.
- Human genetic variants of these channels have not been associated with any inherited clinical disorder.
- aberrant expression of Na v 1.8 has been found in the CNS of human multiple sclerosis (MS) patients and also in a rodent model of MS (Black et al, Proc. Natl. Acad. Sci. USA 97:11598-115602 (2000)).
- Evidence for involvement in nociception is both associative (preferential expression in nociceptive neurons) and direct (genetic knockout).
- the Na v 1.7 (PN1, SCN9A) VGSC is sensitive to blocking by tetrodotoxin and is preferentially expressed in peripheral sympathetic and sensory neurons.
- the SCN9A gene has been cloned from a number of species, including human, rat, and rabbit and shows -90 % amino acid identity between the human and rat genes (Toledo-Aral et al, Proc. Natl. Acad. Sci. USA 94: 1527- 1532 (1997)).
- Sodium channel-blocking agents have been reported to be effective in the treatment of various disease states, and have found particular use as local anesthetics, e.g., lidocaine and bupivacaine, and in the treatment of cardiac arrhythmias, e.g., propafenone and amiodarone, and epilepsy, e.g., lamotrigine, phenytoin and carbamazepine (see Clare et al., Drug Discovery Today 5:506-510 (2000); Lai et al, Annu. Rev. Pharmacol. Toxicol. 44:371- 397 (2004); Anger et al., J. Med Chem. 44:115-137 (2001), and Catterall, Trends Pharmacol. Sci. 8:57-65 (1987)). Each of these agents is believed to act by interfering with the rapid influx of sodium ions.
- local anesthetics e.g., lidocaine and bupivacaine
- sodium channel-blocking agents can be useful in the treatment of pain, including acute, chronic, inflammatory, neuropathic, and other types of pain such as rectal, ocular, and submandibular pain typically associated with paroxysmal extreme pain disorder; see, for example, Kyle and Ilyia, J Med. Chem. 50:2583-2588 (2007); Wood et al, J.
- neurological disorders such as epilepsy, seizures, epilepsy with febrile seizures, epilepsy with benign familial neonatal infantile seizures, inherited pain disorders, e.g., primary
- carbamazepine, lidocaine and phenytoin are used to treat neuropathic pain, such as from trigeminal neuralgia, diabetic neuropathy and other forms of nerve damage (Taylor and Meldrum, Trends Pharmacol. Sci. 75:309-316 (1995)). Furthermore, based on a number of similarities between chronic pain and tinnitus, (Moller, Am. J. Otol. 75:577-585 (1997); Tonndorf, Hear. Res.
- tinnitus should be viewed as a form of chronic pain sensation (Simpson, et al, Tip. 20:12-18 (1999)). Indeed, lidocaine and carbamazepine have been shown to be efficacious in treating tinnitus (Majumdar, B. et al, Clin. Otolaryngol. 5:175-180 (1983); Donaldson, Laryngol. Otol. 95:947-951 (1981)).
- the present invention is related to the use of substituted pyridine compounds represented by Formula I, below, and the pharmaceutically acceptable salts, prodrugs and solvates thereof (collectively referred to herein as "Compounds of the Invention"), as blockers of sodium (Na + ) channels.
- the present invention is also related to treating a disorder responsive to the blockade of sodium channels in a mammal suffering from excess activity of said channels by administering an effective amount of a Compound of the Invention as described herein.
- Some compounds useful in the present invention have not been heretofore reported.
- one aspect of the present invention is directed to novel compounds of Formula I, as well as their pharmaceutically acceptable salts, prodrugs and solvates.
- Another aspect of the present invention is directed to the use of the novel compounds of Formula I, and their pharmaceutically acceptable salts, prodrugs and solvates, as blockers of sodium channels.
- a further aspect of the present invention is to provide a method for treating pain (e.g., acute pain, chronic pain, which includes but is not limited to, neuropathic pain, postoperative pain, and inflammatory pain, or surgical pain) by administering an effective amount of a Compound of the Invention to a mammal in need of such treatment.
- pain e.g., acute pain, chronic pain, which includes but is not limited to, neuropathic pain, postoperative pain, and inflammatory pain, or surgical pain
- the present invention provides a method for preemptive or palliative treatment of pain by administering an effective amount of a Compound of the Invention to a mammal in need of such treatment.
- a further aspect of the present invention is to provide a method for treating stroke, neuronal damage resulting from head trauma, epilepsy, seizures, general epilepsy with febrile seizures, severe myoclonic epilepsy in infancy, neuronal loss following global and focal ischemia, migraine, familial primary erythromelalgia, paroxysmal extreme pain disorder, cerebellar atrophy, ataxia, dystonia, tremor, mental retardation, autism, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), manic depression, tinnitus, myotonia, a movement disorder, or cardiac arrhythmia, or providing local anesthesia, by administering an effective amount of a Compound of the Invention to a mammal in need of such treatment.
- ALS amyotrophic lateral sclerosis
- a further aspect of the present invention is to provide a pharmaceutical composition useful for treating a disorder responsive to the blockade of sodium ion channels, said pharmaceutical composition containing an effective amount of a Compound of the Invention in a mixture with one or more pharmaceutically acceptable carriers.
- an aspect of the present invention is to provide a method of modulating sodium channels in a mammal, wherein said method comprises administering to the mammal an effective amount of at least one Compound of the Invention.
- a further aspect of the present invention is to provide a Compound of the Invention for use in treating pain in a mammal, e.g., acute pain, chronic pain, which includes but is not limited to, neuropathic pain, postoperative pain, and inflammatory pain, or surgical pain.
- a mammal e.g., acute pain, chronic pain, which includes but is not limited to, neuropathic pain, postoperative pain, and inflammatory pain, or surgical pain.
- a further aspect of the present invention is to provide a Compound of the Invention for use in treating stroke, neuronal damage resulting from head trauma, epilepsy, seizures, general epilepsy with febrile seizures, severe myoclonic epilepsy in infancy, neuronal loss following global and focal ischemia, migraine, familial primary erythromelalgia, paroxysmal extreme pain disorder, cerebellar atrophy, ataxia, dystonia, tremor, mental retardation, autism, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), manic depression, tinnitus, myotonia, a movement disorder, or cardiac arrhythmia, or providing local anesthesia, in a mammal.
- a neurodegenerative disorder e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease
- ALS amyotrophic lateral sclerosis
- a further aspect of the present invention is to provide radiolabeled
- the present invention further provides a method for screening a candidate compound for its ability to bind to a sodium channel or sodium channel subunit using a radiolabeled Compound of the Invention.
- the compound is radiolabeled with 3 H, U C, or 14 C. This competitive binding assay can be conducted using any appropriately selected methodology.
- the screening method comprises: i) introducing a fixed concentration of the radiolabeled compound to an in vitro preparation comprising a soluble or membrane-associated sodium channel, subunit or fragment under conditions that permit the radiolabeled compound to bind to the channel, subunit or fragment, respectively, to form a conjugate; ii) titrating the conjugate with a candidate compound; and iii) determining the ability of the candidate compound to displace the radiolabeled compound from said channel, subunit or fragment.
- a further aspect of the present invention is to provide the use of a
- the invention provides the use of a Compound of the Invention in the manufacture of a medicament for palliative or preemptive treatment of pain, such as acute pain, chronic pain, or surgical pain.
- a further aspect of the present invention is to provide the use of a
- Compound of the Invention in the manufacture of a medicament for treating stroke, neuronal damage resulting from head trauma, epilepsy, seizures, general epilepsy with febrile seizures, severe myoclonic epilepsy in infancy, neuronal loss following global and focal ischemia, migraine, familial primary erythromelalgia, paroxysmal extreme pain disorder, cerebellar atrophy, ataxia, dystonia, tremor, mental retardation, autism, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), manic depression, tinnitus, myotonia, a movement disorder, or cardiac arrhythmia, or providing local anesthesia, in a mammal.
- a neurodegenerative disorder e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease
- ALS amyotrophic lateral sclerosis
- a neurodegenerative disorder e.g.
- One aspect of the present invention is based on the use of compounds of Formula I, and the pharmaceutically acceptable salts, prodrugs and solvates thereof, as blockers of Na + channels.
- compounds of Formula I, and the pharmaceutically acceptable salts, prodrugs and solvates thereof are useful for treating disorders responsive to the blockade of sodium ion channels.
- Z is selected from the group consisting of N and N-oxide and Z is CR lb ; or
- Z 1 is CR lb and Z 2 is selected from the group consisting of N and N- oxide;
- R ,a and R lb which are identical or different, are selected from the group consisting of:
- a 1 is selected from the group consisting of:
- X is selected from the group consisting of:
- R 2 and R 3 which are identical or different, are selected from the group consisting of hydrogen, fluoro, and optionally substituted alkyl; or
- R and R taken together with the carbon atom to which they are attached form a 3- to 8-membered optionally substituted cycloalkyl or optionally substituted heterocyclo;
- R 4 is selected from the group consisting of hydrogen and optionally substituted alkyl
- A is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- G is selected from the group consisting of:
- R 5a and R 5b which are identical or different, are selected from the group consisting of:
- R 5a and R 5b taken together with the nitrogen atom to which they are attached form an optionally substituted 3- to 8-membered heterocyclo;
- R 6a and R 6b which are identical or different, are selected from the group consisting of:
- R is selected from the group consisting of:
- R 8a and R 8b which are identical or different, are selected from the group consisting of:
- L is selected from the group consisting of -O- and -NR 16 -;
- R 9 is selected from the group consisting of hydrogen, alkyl, and
- R 15a , R 15b , R 15c , R 15d , and R 15e which are identical or different, are selected from the group consisting of hydrogen and optionally substituted alkyl;
- R 16 is selected from the group consisting of hydrogen and optionally substituted alkyl; [0052] m, n, o, p, and q are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or
- w is 0, 1, 2, 3, 4, or 5;
- x and y are each independently 1, 2, 3, or 4;
- E is selected from the group consisting of:
- R 17a and R 17b which are identical or different, are selected from the group consisting of: a) hydrogen;
- R 17a and R 17 taken together with the nitrogen atom to which they are attached form an optionally substituted 3- to 8-membered heterocyclo;
- R 18a and R 18b which are identical or different, are selected from the group consisting of:
- R 18a and R 18b taken together with the nitrogen atom to which they are attached form an optionally substituted 3- to 8-membered heterocyclo;
- R 19 is selected from the group consisting of hydrogen and optionally substituted alkyl
- R 20a and R 20b which are identical or different, are selected from the group consisting of hydrogen and optionally substituted alkyl, wherein at least one of R 20a and R 20b is optionally substituted alkyl;
- R 21a is selected from the group consisting of hydrogen and alkyl
- R 21b and R 21c which are identical or different, are selected from the group consisting of:
- R 1b and R 21c taken together with the nitrogen atom to which they are attached form an optionally substituted 3- to 8-membered heterocyclo;
- R 22 is selected from the group consisting of hydrogen and alkyl;
- R a is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
- R 24b is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
- t and u are each independently 0, 1 , 2, or 3;
- v is 1, 2, or 3.
- Compounds of the Invention are compounds having Formula I, wherein G and E are not both hydrogen.
- Compounds of the Invention are compounds having Formula I, wherein when G is alkyl, then E is not halogen.
- Compounds of the Invention are compounds having Formula I, wherein when G is:
- E is not a morpholinyl group.
- Compounds of the Invention are compounds having Formula I, wherein when G is:
- R 17a and R 17b are not both hydrogen, R 17a and R 17b are not both alkyl, RR 1177aa iiss nnoott hydrogen when R 17b is alkyl, and R 17a is not alkyl when R 17b is hydrogen.
- Compounds of the Invention are compounds having Formula I, wherein when G is:
- Compounds of the Invention are compounds having Formula I, wherein when G is: [0076] and w is 0, then E is:
- R 17a and R 17b are not hydrogen or optionally substituted alkyl and u is 1, 2, or 3.
- Compounds of the Invention are compounds having Formula I, wherein when G is: - 9 G - 5
- R 9 is hydrogen or alkyl; then E is:
- Compounds of the Invention are compounds having Formula I, wherein:
- G is selected from the group consisting of:
- E is selected from the group consisting of:
- hydroxyalkyl including, e.g., -CH(OH)CH 2 OH,
- Compounds of the Invention are compounds having Formula I, wherein when G is:
- R 5a and R 5b taken together with the nitrogen atom to which they are attached form an optionally substituted 3- to 8-membered heterocyclo, then said optional substituents are selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, alkylcarbonyl,
- arylcarbonyl ureido, guanidino, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl,
- Compounds of the Invention are compounds having Formula I, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: [0084] Z 1 is selected from the group consisting of N and N-oxide and Z is
- Z 1 is CH and Z 2 is selected from the group consisting of N and N-oxide
- R la is hydrogen
- a 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- X is selected from the group consisting of:
- a 2 is unsubstituted phenyl
- G is selected from the group consisting of:
- R 5a and R 5b are hydrogen; [0092] R 6a is selected from the group consisting of:
- R 6b is selected from the group consisting of hydrogen and
- R 7 is -(CH 2 CH 2 0)o-R 15c ;
- R 8a and R 8b are hydrogen
- L is -0-
- R 15c is selected from the group consisting of hydrogen and optionally substituted alkyl
- o is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11;
- x is 1 or 2;
- E is selected from the group consisting of:
- R 17a is selected from the group consisting of hydrogen and alkyl
- R 17b is selected from the group consisting of:
- R 18a and R 18b are hydrogen
- R 21a is selected from the group consisting of hydrogen and alkyl
- R 21b and R 21c which are identical or different, are selected from the group consisting of:
- R 21b and R 21c taken together with the nitrogen atom to which they are attached form an optionally substituted 3- to 8-membered heterocyclo;
- t is 0 or l
- u is O
- G is G-2, G-3, or G-4.
- Compounds of the Invention are compounds having Formula II:
- Compounds of the Invention are compounds having Formula III:
- Compounds of the Invention are compounds having Formula IV:
- a 1 , X, A 2 , R la , R 5a , R 5b , Z 1 , Z 2 , and w are as defined above in connection with Formula I, and E is selected from the group consisting of : a) optionally substituted heteroaryl;
- R 17a , R 17b , R 18a , R 18b , R 19 , R 20a , R 20b , R 21a , R 2,b , R 21c , R 22 , t, u, and v are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula IV and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein w is 0.
- Compounds of the Invention are compounds having Formula IV and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein E is hydroxyalkyl.
- Useful hydroxyalkyl groups include:
- Compounds of the Invention are compounds having Formula V:
- a 1 , X, A 2 , R la , R lb , R 5a , R 5b , z Z 2 , and w are as defined above in connection with Formula I, and E is selected from the group consisting of : a) optionally substituted heteroaryl;
- R 17a , R 17b , R 18a , R 18b , R 19 , R 20a , R 20b , R 21a , R 21b , R 21c , R 22 , t, u, and v are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula V and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein w is 0.
- Compounds of the Invention are compounds having Formula V and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein E is hydroxyalkyl.
- Useful hydroxyalkyl groups include:
- Compounds of the Invention are compounds having Formula V and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein:
- R 17a is selected from the group consisting of:
- R 17b is selected from the group consisting of:
- R 17a and R 17b taken together with the nitrogen atom to which they are attached form an optionally substituted 3- to 8-membered heterocyclo.
- Compounds of the Invention are compounds having Formula V and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein E is:
- u 1, 2, or 3.
- Compounds of the Invention are compounds having Formula VI:
- a 1 , X, A 2 , R la , R lb , R 5a , R 5b , and w are as defined above in connection with Formula I, and E is selected from the group consisting of: a) optionally substituted heteroaryl;
- R 17a , R 17b , R 18a , R 18b , R 19 , R 20a , R 20b , R 21a , R 21b , R 21c , R 22 , t, u, and v are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula VI and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein w is 0.
- Compounds of the Invention are compounds having Formula VII:
- a 1 , X, A 2 , R la , R 6a , R 6b , E, Z 1 , Z 2 , and x are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula VIII:
- a 1 , X, A 2 , R la , R lb , R 6a , R 6b , E, and x are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula IX:
- a 1 , X, A 2 , R la , R lb , R 6a , R 6b , E, and x are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula X:
- a 1 , X, A 2 , R la , Z 1 , Z 2 , R 7 , E, and y are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula XI:
- a 1 , X, A 2 , R la , R lb , R 7 , E, and y are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula XII:
- a 1 , X, A 2 , R la , R lb , R 7 , E, and y are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula XIII:
- a 1 , X, A 2 , R la , R 8a , R 8b , E, Z 1 , Z 2 , and L are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula XIV:
- a 1 , X, A 2 , R la , R lb , R 8a , R 8b , E, and L are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula XV:
- a 1 , X, A 2 , R la , R lb , R 8a , R 8b , E, and L are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula XVI:
- a 1 , X, A 2 , R la , R 9 , Z l , Z 2 , and E are as defined above in connection with Formula I.
- Compounds of the Invention are compounds having Formula XVII:
- Compounds of the Invention are compounds having Formula XVIII:
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein A 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl; X is -S-; and A 2 is optionally substituted phenyl; and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein A 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl; X is -SO-; and A 2 is optionally substituted phenyl; and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVTII, wherein A 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- X is -S0 2 -; and A 2 is optionally substituted phenyl; and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein A 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- X is a bond; and A 2 is optionally substituted phenyl; and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein A 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- X is -CH 2 -; and A 2 is optionally substituted phenyl; and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein A 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- X is -NH-; and A 2 is optionally substituted phenyl; and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein A 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- X is -S0 2 NH-; and A 2 is optionally substituted phenyl; and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein A 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein A 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl; X is -0-; and A is optionally substituted phenyl; and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein A 1 is selected from the group consisting of optionally substituted phenyl; optionally substituted pyridin-2- yl; optionally substituted pyridin-3-yl; and optionally substituted pyridin-4-yl; X is -0-; and A 2 is optionally substituted phenyl; and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein A -X-A - is:
- R 23a , R 23b , R 23c , R 23d , R 23e which are identical or different, are selected from the group consisting of:
- R 23a and R 23b , or R 23b and R 23c , or R 23c and R 23d , or R 23d and R 23e taken together with the carbon atoms to which they are attached form a 5- or 6-membered optionally substituted cycloalkyl or heterocyclo group; and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- R 23a , R 23b , R 23c , R 3d , R 23e which are identical or different, are selected from the group consisting of: a) hydrogen;
- R 23a and R 23b , or R 23b and R 23c , or R 23c and R 23d , or R 23d and R 23e taken together with the carbon atoms to which they are attached form a 5- or 6- membered optionally substituted cycloalkyl or heterocyclo group.
- R 23a , R 23b , R 23c , R 23d , R 23e which are identical or different, are selected from the group consisting of:
- R 23a and R 23b , or R 23b and R 23c , or R 23c and R 23d , or R 23d and R 23e taken together with the carbon atoms to which they are attached form a 5- or 6- membered optionally substituted cycloalkyl or heterocyclo group.
- R 23d , or R 23d and R 23e taken together represent: -CH 2 CH 2 0-; -OCH 2 0-; - OCH 2 CH 2 CH 2 0-; -OCH 2 CH 2 0-; -CH 2 CH 2 CH 2 -; -CH 2 CH 2 CH 2 CH 2 -; -NR 25a CH 2 CH 2 -; -CH 2 NR 25b CH 2 -; -NR 25c CH 2 CH 2 CH 2 -; or -CH 2 NR 25d CH 2 CH 2 -, wherein R 25a , R 25b , R 25c , and R 25d , which are identical or different, are selected from the group consisting of hydrogen and optionally substituted alkyl.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein R ,a and R lb are each hydrogen, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein E is optionally substituted heteroaryl, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein E is optionally substituted heterocyclo, e.g., an optionally subsituted piperidine or optionally substituted piperazine, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- E is optionally substituted heterocyclo, e.g., an optionally subsituted piperidine or optionally substituted piperazine, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae I-XVIII wherein E is hydroxyalkyl.
- Useful hydroxyalkyl groups include:
- Compounds of the Invention are compounds having any one of Formulae I-XVIII wherein E is:
- Compounds of the Invention are compounds having any one of Formulae I-XVIII wherein E is:
- t 17a is hydrogen
- R 17b is (carboxamido)alkyl, e.g.,
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein E is:
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein E is:
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein E is:
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein E is:
- Compounds of the Invention are compounds having any one of Formulae I-XVIII, wherein E is:
- Compounds of the Invention are compounds having Formula V, wherein w is 0 and E is optionally substituted heteroaryl, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula V, wherein w is 0 and E is optionally substituted heterocyclo, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula V, wherein w is 0 and E is hydroxyalkyl, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula V, wherein w is 0 and E is:
- Compounds of the Invention are compounds having Formula V, wherein w is 0 and E is:
- Compounds of the Invention are compounds having Formula V, wherein w is 0 and E is:
- Compounds of the Invention are compounds having Formula V, wherein w is 0 and E is:
- Compounds of the Invention are compounds having Formula V, wherein w is 0 and E is:
- Compounds of the Invention are compounds having Formula V, wherein w is 0 and E is:
- Compounds of the Invention are compounds having Formula XIX:
- R is -(CH2CH 2 0)o-R 15c and R 15c is H, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formulf
- a 1 and E are as defined above in connection with Formula I, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formu
- a 1 and E are as defined above in connection with Formula I, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXII:
- a and E are as defined above in connection with Formula I, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXIII:
- a 1 , R 5a , and R 5b are as defined above in connection with Formula I and E is hydroxyalkyl.
- Useful hydroxyalkyl groups include:
- Compounds of the Invention are compounds having Formula XXIV:
- a 1 , R 5a , and R 5b are as defined above in connection with Formula I and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXV:
- a 1 , R 5a , and R 5b are as defined above in connection with Formula I, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXVI:
- a 1 , R 5a , and R 5b are as defined above in connection with Formula I, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXVII:
- a 1 , R 5a , R 5b R 17a , R 17b , and t are as defined above in connection with Formula I, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXVII, wherein A 1 , R 5a , R 5b R 17a , and R 17b are as defined above in connection with Formula I and t is 0 or 1, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXVII, wherein A 1 , R 5a , and R 5b are as defined above in connection with Formula I, t is 0, R 17a is selected from the group consisting of:
- R is selected from the group consisting of:
- R 17a and R 17b taken together with the nitrogen atom to which they are attached form an optionally substituted 3- to 8-membered heterocyclo, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXVII, wherein A 1 , R 5a , and R 5b are as defined above in connection with Formula I, t is 0, R 17a is hydrogen, and R 17b is (carboxamido)alkyl, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXVII, wherein A 1 is optionally substituted aryl, R 5a and R 5b are hydrogen, t is 0, R 17a is hydrogen, and R 17b is (carboxamido)alkyl, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXVIII: XXVIII, wherein A 1 , R bb , and x are as defined above in connection with Formula I, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof,.
- Compounds of the Invention are compounds having Formula XXVIII, wherein A 1 and R 6b are as defined above in connection with Formula I and x is 1 or 2, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXIII wherein E is optionally substituted heteroaryl, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Useful optionally substituted heteroaryl groups include optionally substituted indoles.
- Compounds of the Invention are compounds having Formula XXIII, wherein E is an optionally substituted heterocyclo, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- E is an optionally substituted piperazinyl having the formula:
- R is chosen from hydrogen, hydroxyalkyl, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, and the like.
- Compounds of the Invention are compounds having Formula XXIX:
- Compounds of the Invention are compounds having Formula XXX:
- a 1 , R 18a , and R 18b are as defined above in connection with Formula I, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof,.
- Compounds of the Invention are compounds having Formula XXXI:
- a 1 , R 18a , and R 18b are as defined above in connection with Formula I, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof,.
- Compounds of the Invention are compounds having Formula XXXII:
- R 17a , R 17b , R 18a , R 18b , R 19 , R 20a , R 20b , t, u, and v are as defined above in connection with Formula I, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXXII wherein E is hydroxyalkyl, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXXII wherein E is optionally substituted heteroaryl, e.g., optionally substituted indole, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having Formula XXXIII:
- R 17a is chosen from hydrogen, alkyl, and optionally substituted aryl.
- R is chosen from (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (carboxamido)alkyl, (cyano)alkyl; and hydroxyalkyl.
- R 17a is optionally substituted aryl and R is (carboxamido)alkyl.
- Compounds of the Invention are compounds having any one of Formulae XIX-XXXIII wherein A 1 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention are compounds having any one of Formulae XIX-XXXIII wherein A 1 is selected from the group consisting of optionally substituted phenyl, optionally substituted pyridin-2-yl, optionally substituted pyridin-3-yl, and optionally substituted pyridin-4-yl, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof.
- Compounds of the Invention include the compound (“cpd”) examples of TABLE 2, and the pharmaceutically acceptable salts, prodrugs, and solvates thereof. TABLE 2
- alkyl refers to a straight- or branched-chain aliphatic hydrocarbon containing one to twelve carbon atoms (i.e., C 1-12 alkyl) or the number of carbon atoms designated (i.e., a Cj alkyl such as methyl, a C 2 alkyl such as ethyl, a C 3 alkyl such as propyl or isopropyl, etc.).
- the alkyl group is chosen from a straight chain C 1-10 alkyl group.
- the alkyl group is chosen from a branched chain C 1-10 alkyl group.
- the alkyl group is chosen from a straight chain C 1-6 alkyl group. In another embodiment, the alkyl group is chosen from a branched chain C 1-6 alkyl group. In another embodiment, the alkyl group is chosen from a straight chain CM alkyl group. In another embodiment, the alkyl group is chosen from a branched chain C 1-4 alkyl group. In another embodiment, the alkyl group is chosen from a C 2-4 alkyl group.
- Non-limiting exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, /ert-butyl, wo-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, decyl, and the like.
- Non-limiting exemplary C 1-4 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, and MO-butyl.
- the term "optionally substituted alkyl" as used by itself or as part of another group means that the alkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from nitro, haloalkoxy, aryloxy, aralkyloxy, alkylthio, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, cycloalkyl, and the like.
- the optionally substituted alkyl is substituted with two substituents.
- the optionally substituted alkyl is substituted with one substituent.
- Non-limiting exemplary optionally substituted alkyl groups include -CH 2 CH 2 N0 2 , -CH 2 CH 2 C0 2 H, - CH 2 CH 2 S0 2 CH 3 , -CH 2 CH 2 COPh, and the like.
- cycloalkyl refers to saturated and partially unsaturated (containing one or two double bonds) cyclic aliphatic hydrocarbons containing one to three rings having from three to twelve carbon atoms (i.e., C 3-12 cycloalkyl) or the number of carbons designated.
- the cycloalkyl group has two rings.
- the cycloalkyl group has one ring.
- the cycloalkyl group is chosen from a C 3 -C 8 cycloalkyl group.
- the cycloalkyl group is chosen from a C 3 -C 6 cycloalkyl group.
- Non-limiting exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, and the like.
- the term "optionally substituted cycloalkyl" as used by itself or as part of another group means that the cycloalkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxyalkyl, (amino)al
- the optionally substituted cycloalkyl is substituted with two substituents. In another embodiment, the optionally substituted cycloalkyl is substituted with one substituent.
- Non-limiting exemplary optionally substituted cycloalkyl groups include:
- alkenyl refers to an alkyl group as defined above containing one, two or three carbon-to-carbon double bonds.
- the alkenyl group is chosen from a C 2-12 alkenyl group.
- the alkenyl group is chosen from a C 2-10 alkenyl group.
- the alkenyl group is chosen from a C 2-6 alkenyl group.
- the alkenyl group is chosen from a C 2 _4 alkenyl group.
- Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, andthe like.
- the term "optionally substituted alkenyl” as used herein by itself or as part of another group means the alkenyl as defined above is either unsubstituted or substituted with one, two or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclo.
- alkynyl refers to an alkyl group as defined above containing one to three carbon-to-carbon triple bonds. In one embodiment, the alkynyl has one carbon-to-carbon triple bond. In one embodiment, the alkynyl group is chosen from a C 2-12 alkynyl group. In one embodiment, the alkynyl group is chosen from a C 2-10 alkynyl group. In one embodiment, the alkynyl group is chosen from a C 2-6 alkynyl group. In another embodiment, the alkynyl group is chosen from a C 2-4 alkynyl group.
- Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.
- alkynyl as used herein by itself or as part of another group means the alkynyl as defined above is either unsubstituted or substituted with one, two or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclo.
- haloalkyl as used by itself or as part of another group refers to an alkyl group as defined above substituted by one or more fluorine, chlorine, bromine and/or iodine atoms.
- the alkyl group is subsituted by one, two, or three fluorine and/or chlorine atoms.
- the haloalkyl group is chosen from a C 1-4 haloalkyl group.
- Non-limiting exemplary haloalkyl groups include fiuoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and trichloromethyl groups.
- hydroxyalkyl refers to an alkyl group as defined above substituted with one or more, e.g., one, two, or three, hydroxy groups.
- the hydroxyalkyl is a monohydroxyalkyl, i.e., substituted with one hydroxy group.
- the hydroxyalkyl is a dihydroxyalkyl, i.e., substituted with two hydroxy groups.
- the hydroxyalkyl group is chosen from a C 1-4 hydroxyalkyl group.
- Non-limiting exemplary hydroxyalkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups, such as 1-hydroxyethyl, 2-hydroxyethyl, 1 ,2-dihydroxyethyl, 2-hydroxypropyl, 3- hydroxypropyl, 3 -hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-l-methylpropyl, and l,3-dihydroxyprop-2-yl.
- alkoxy refers to an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl attached to a terminal oxygen atom.
- the alkoxy group is chosen from a C 1-4 alkoxy group.
- the alkoxy group is chosen from a C 1-4 alkyl attached to a terminal oxygen atom, e.g., methoxy, ethoxy, and tert-butoxy.
- alkylthio refers to a sulfur atom substituted by an optionally substituted alkyl group.
- the alkylthio group is chosen from a C alkylthio group.
- Non-limiting exemplary alkoxy groups include -SCH 3 , and -SCH 2 CH 3 .
- alkoxyalkyl refers to any of the above-mentioned alkyl groups substituted with any of the above-mentioned alkoxy groups.
- Non-limiting exemplary alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, iso-propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sec-butoxymethyl, and pentyloxymethyl.
- haloalkoxy as used by itself or as part of another group refers to a haloalkyl attached to a terminal oxygen atom.
- Non-limiting exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2- trifluoroethoxy.
- aryloxy as used by itself or as part of another group refers to an optionally substituted aryl attached to a terminal oxygen atom.
- a non-limiting exemplary aryloxy group is PhO-.
- aralkyloxy as used by itself or as part of another group refers to an aralkyl group attached to a terminal oxygen atom.
- a non-limiting exemplary aryloxy group is
- aryl refers to a monocyclic or bicyclic aromatic ring system having from six to fourteen carbon atoms (i.e., C 6 -C 14 aryl).
- Non-limiting exemplary aryl groups include phenyl (abbreviated as "Ph"), naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups.
- the aryl group is chosen from phenyl and naphthyl.
- the term "optionally substituted aryl" as used herein by itself or as part of another group means that the aryl as defined above is either unsubstituted or substituted with one to five substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxyalkyl, (amino)alkyl, hydroxyalkyl, hydroxyalkyl
- the optionally substituted aryl is an optionally substituted phenyl. In one embodiment, the optionally substituted phenyl has four substituents. In another embodiment, the optionally substituted phenyl has three substituents. In another embodiment, the optionally substituted phenyl has two substituents. In another embodiment, the optionally substituted phenyl has one substituent.
- Non-limiting exemplary substituted aryl groups include 2- methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2- bromophenyl, 3-methylphenyl, 3-methoxyphenyl, 3 -fluorophenyl, 3- chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4- fluorophenyl, 4-chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2- methyl, 3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl 3,5-di-methylphenyl and 3,5-dimethoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, and 3-chloro-4-fluorophenyl.
- heteroaryl refers to monocyclic and bicyclic aromatic ring systems having 5 to 14 ring atoms (i.e., C 5 -C 14 heteroaryl) and 1, 2, 3, or 4 heteroatoms independently chosen from oxygen, nitrogen and sulfur.
- the heteroaryl has three heteroatoms.
- the heteroaryl has two heteroatoms.
- the heteroaryl has one heteroatom.
- the heteroaryl is a C 5 heteroaryl.
- the heteroaryl is a C heteroaryl.
- Non-limiting exemplary heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3- b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H- indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, ⁇ -carbolin
- the heteroaryl is chosen from thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., lH-pyrrol-2-yl and lH-pyrrol-3-yl), imidazolyl (e.g., 2H-imidazol-2-yl and 2H-imidazol-4-yl), pyrazolyl (e.g., lH-pyrazol-3-yl, lH-pyrazol-4-yl, and lH-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3- yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, and pyr
- the term "optionally substituted heteroaryl" as used by itself or as part of another group means that the heteroaryl as defined above is either unsubstituted or substituted with one to four substituents, e.g., one or two substituents, independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxyalkyl, (
- the optionally substituted heteroaryl has one substituent.
- the optionally substituted is an optionally substituted pyridyl, i.e., 2-, 3-, or 4-pyridyl. Any available carbon or nitrogen atom can be substituted.
- the optionally substituted heteroaryl is an optionally substituted indole.
- heterocyclo refers to saturated and partially unsaturated (containing one or two double bonds) cyclic groups containing one to three rings having from two to twelve carbon atoms (i.e., C 2 -C 12 heterocyclo) and one or two oxygen, sulfur and/or nitrogen atoms.
- heterocyclo is meant to include cyclic ureido groups such as 2-imidazolidinone.
- the heterocyclo group is chosen from a 5- or 6-membered cyclic group containing one ring and one or two oxygen and/or nitrogen atoms.
- heterocyclo can be optionally linked to the rest of the molecule through a carbon or nitrogen atom.
- Non-limiting exemplary heterocyclo groups include 2-imidazolidinone, pipendinyl, morpholinyl, piperazinyl, and pyrrolidinyl.
- heterocyclo as used herein by itself or part of another group means the heterocyclo as defined above is either unsubstituted or substituted with one to four substituents independently selected from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino
- Substitution may occur on any available carbon or nitrogen atom.
- An optionally substituted heterocyclo can be fused to an aryl group to provide an optionally substituted aryl as described above.
- the optionally substituted heterocyclo is a substituted piperazine.
- Non-limiting exemplary optionally substituted heterocyclo groups include:
- amino as used by itself or as part of another group refers to -NH 2 .
- aminoalkyl refers to any of the above-mentioned alkyl groups substituted with an amino group.
- Non-limiting exemplary amino alkyl groups include -CH 2 CH 2 NH 2 , -CH 2 CH 2 CH 2 NH 2 ,
- diaminoalkyl as used by itself or as part of another group refers any of the above-mentioned alkyl groups substituted with two amino groups.
- alkylamino as used by itself or as part of another group refers to -NHR , wherein R is any alkyl group as "alkyl” is defined above.
- dialkylamino as used by itself or as part of another group refers to -NR 27a R 27b wherein R 27a and R are each independently any alkyl group as "alkyl” is defined above.
- hydroxyalkylamino as used by itself or as part of another group refers to -
- NHR 28 wherein R 28 is any hydroxyalkyl group as "hydroxyalkyl" is defined above.
- alkylaminoalkyl as used by itself or as part of another group refers to any alkyl group as “alkylamino” is defined above.
- dialkylamino)alkyl refers to any alkyl group as “alkyl” is defined above substituted by any dialkylamino group as “dialkylamino” is defined above.
- (cyano)alkyl refers to any alkyl group as "alkyl” is defined above substituted with one or more cyano, e.g., -CN, groups.
- Non- limiting exemplary (cyano)alkyl groups include -CH 2 CH 2 CN, -CH 2 CH 2 CH 2 CN, and -CH 2 CH 2 CH 2 CH 2 CN.
- Non-limiting exemplary carboxamido groups include -CONH 2 , -CON(H)CH 3 , CON(CH 3 ) 2 , and CON(H)Ph.
- (carboxamido)alkyl as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted with a carboxamido rou .
- Non-limitin exem lary (carboxamido)alkyl groups include:
- sulfonamido refers to a radical of the formula -S0 2 NR 34a R 34b , wherein R 34a and R 34b are each independently hydrogen, optionally substituted alkyl, or optionally substituted aryl, or R 34a and R 34b taken together with the nitrogen to which they are attached from a 3- to 8- membered heterocyclo group
- Non-limiting exemplary sulfonamido groups include -S0 2 NH 2 , -S0 2 N(H)CH 3 , and -S0 2 N(H)Ph.
- a non-limiting exemplary alkylcarbonyl group is -COCH 3 .
- a non-limiting exemplary arylcarbonyl group is -COPh.
- alkylsulfonyl as used by itself or as part of another group refers to a sulfonyl group, i.e., -S0 2 , substituted by any of the above-mentioned optionally substituted alkyl groups.
- a non-limiting exemplary alkylsulfonyl group is -S0 2 CH 3 .
- arylsulfonyl as used by itself or as part of another group refers to a sulfonyl group, i.e., -S0 2 , substituted by any of the above-mentioned optionally substituted aryl groups.
- a non-limiting exemplary arylsulfonyl group is -S0 2 Ph.
- mercaptoalkyl as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted by a -SH group.
- carboxy as used by itself or as part of another group refers to a radical of the formula -COOH.
- the term "carboxyalkyl” as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted with a -COOH.
- a non-limiting exemplary carboxyalkyl group is -CH 2 C0 2 H.
- the term “aralkyl” as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted with one, two, or three optionally substituted aryl groups.
- the aralkyl group is a C 1-4 alkyl substituted with one optionally substituted aryl group.
- Non-limiting exemplary aralkyl groups include benzyl and phenethyl.
- the term "azido" as used by itself or as part of another group refers to a radical of the formula -N 3 .
- (heterocyclo)alkyl as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted with one, two, or three optionally substituted heterocyclo groups.
- the (heterocyclo)alkyl group is a C 1-4 alkyl substituted with one optionally substituted heterocyclo group.
- Non-limiting exemplary (heterocyclo)alkyl groups include:
- the term "(heteroaryl)alkyl” as used by itself or as part of another group refers to any of the above- mentioned alkyl groups substituted with one, two, or three optionally substituted heteroaryl groups.
- the (heteroaryl)alkyl group is a C 1-4 alkyl substituted with one optionally substituted heteroaryl group.
- Non-limiting exemplary (heteroaryl)alkyl groups include:
- alkylcarbonylamino as used by itself or as part of another group refers to an alkylcarbonyl group attached to an amino nitrogen.
- a non-limiting exemplary alkylcarbonylamino group is -NHCOCH 3 .
- the group -S0 2 NH- is intended to connect Ai and A 2 in either direction, i.e., Ai-S0 2 NH-A 2 - or Aj- NHS0 2 -A 2 -.
- X is -S0 2 NH-.
- X is -NHS0 2 -.
- prodrugs are considered to be any covalently bonded carriers that release the active parent drug in vivo.
- prodrugs will be functional derivatives of compounds of any of Formulae I-XXXIII, which will be readily convertible in vivo, e.g., by being metabolized, into the required compound of Formulae I-XXXIII.
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, Design of Prodrugs, H. Bundgaard ed., Elsevier (1985); "Drug and Enzyme Targeting, Part A," K. Widder et al.
- Non-limiting examples of prodrugs include esters or amides of compounds of any of Formulae I-XXXIII having hydroxyalkyl or aminoalkyl as a substituent, and these can be prepared by reacting such parent compounds with anhydrides such as succinic anhydride.
- the invention disclosed herein is also intended to encompass any of the disclosed compounds being isotopically-labelled (i.e., radiolabeled) by having one or more atoms replaced by an atom having a different atomic mass or mass number.
- isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, n C, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 C1, respectively, and preferably 3 H, n C, and 14 C.
- Isotopically-labeled compounds of the present invention can be prepared by methods known in the art.
- the present invention is also directed to 3 H, U C, or 14 C radiolabeled compounds of any of Formulae I-XXXIII, as well as their pharmaceutically acceptable salts, prodrugs and solvates, and the use of any such compounds as radioligands for their ability to bind to the sodium channel.
- one use of the labeled compounds of the present invention is the characterization of specific receptor binding.
- Another use of a labeled compound of the present invention is an alternative to animal testing for the evaluation of structure-activity relationships.
- the receptor assay can be performed at a fixed concentration of a labeled compound of the invention and at increasing concentrations of a test compound in a competition assay.
- a tritiated compound of any of Formulae I- XXXIII can be prepared by introducing tritium into the particular compound, for example, by catalytic dehalogenation with tritium.
- This method may include reacting a suitably halogen-substituted precursor of the compound with tritium gas in the presence of a suitable catalyst, for example, Pd/C, in the presence or absence of a base.
- a suitable catalyst for example, Pd/C
- Other suitable methods for preparing tritiated compounds can be found in Filer, Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987).
- 14 C-labeled compounds can be prepared by employing starting materials having a 14 C carbon.
- Some of the compounds disclosed herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms.
- the present invention is meant to encompass the use of all such possible forms, as well as their racemic and resolved forms and mixtures thereof.
- the individual enantiomers can be separated according to methods known in the art in view of the present disclosure.
- the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.
- stereoisomers is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
- chiral center refers to a carbon atom to which four different groups are attached.
- enantiomer and “enantiomeric” refer to a molecule that cannot be superimposed on its mirror image and hence is optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image compound rotates the plane of polarized light in the opposite direction.
- racemic refers to a mixture of equal parts of enantiomers and which mixture is optically inactive.
- resolution refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule.
- treat means to encompass administering to a subject a compound of the present invention for the purposes of amelioration or cure, including preemptive and palliative treatment.
- the invention disclosed herein also encompasses the use of salts of the disclosed compounds, including all non-toxic pharmaceutically acceptable salts thereof of the disclosed compounds.
- pharmaceutically acceptable addition salts include inorganic and organic acid addition salts and basic salts.
- the pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, ⁇ , ⁇ '-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulphate and the like; organic acid salts such as citrate, lactate, tartrate, maleate, fumarate, mandelate, acetate, dichloroacetate, trifluoroacetate, oxalate,
- Acid addition salts can be formed by mixing a solution of the particular compound of the present invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, dichloroacetic acid, or the like.
- Basic salts can be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate and the like.
- solvates typically do not significantly alter the physiological activity or toxicity of the compounds, and as such may function as pharmacological equivalents.
- solvate as used herein is a combination, physical association and/or solvation of a compound of the present invention with a solvent molecule such as, e.g. a disolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to compound of the present invention is 2:1, 1 :1 or 1 :2, respectively.
- This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding.
- solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid.
- solvate encompasses both solution- phase and isolatable solvates.
- Compounds of any of Formulae I-XXXIII can be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, ethanol, and the like, and it is intended that the invention includes both solvated and unsolvated forms of compounds of any of Formulae I-XXXIII.
- a pharmaceutically acceptable solvent such as water, methanol, ethanol, and the like
- solvate includes both solvated and unsolvated forms of compounds of any of Formulae I-XXXIII.
- One type of solvate is a hydrate.
- a "hydrate” relates to a particular subgroup of solvates where the solvent molecule is water.
- Solvates typically can function as pharmacological equivalents.
- solvates Preparation of solvates is known in the art. See, for example, M. Caira et a.l, J. Pharmaceut. Scl, 93 (3) :601 -611 (2004), which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by E.C. van Tonder et al, AAPS Pharm. Sci. Tech., 5(7 :Article 12 (2004), and A.L. Bingham et al., Chem. Commun. : 603-604 (2001).
- a typical, non-limiting, process of preparing a solvate would involve dissolving a compound of any of Formulae I-XXXIII in a desired solvent (organic, water, or a mixture thereof) at temperatures above 20°C to about 25 °C, then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration.
- Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
- compounds of Formulae I-XXXIII are blockers of sodium (Na + ) channels, a number of diseases and conditions mediated by sodium ion influx can be treated by employing these compounds.
- the present invention is thus directed generally to a method for treating a disorder responsive to the blockade of sodium channels in an animal suffering from, or at risk of suffering from, said disorder, said method comprising administering to the animal an effective amount of a compound represented by any of defined Formulae I-XXXIII, or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
- the present invention is further directed to a method of modulating sodium channels in an animal in need thereof, said method comprising administering to the animal a modulating-effective amount of at least one compound represented by any of defined Formulae I-XXXIII, or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
- the present invention provides a method of treating stroke, neuronal damage resulting from head trauma, epilepsy, neuronal loss following global and focal ischemia, pain (e.g., acute pain, chronic pain, which includes but is not limited to neuropathic pain, postoperative pain, and inflammatory pain, or surgical pain), a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), migraine, manic depression, tinnitus, myotonia, a movement disorder, or cardiac arrhythmia, or providing local anesthesia.
- the invention provides a method of treating pain.
- the type of pain is chronic pain.
- the type of pain is neuropathic pain.
- the type of pain is postoperative pain. In another embodiment, the type of pain is inflammatory pain. In another embodiment, the type of pain is surgical pain. In another embodiment, the type of pain is acute pain. In another embodiment, the treatment of pain (e.g., chronic pain, such as neuropathic pain, postoperative pain, or inflammatory pain, acute pain or surgical pain) is preemptive. In another embodiment, the treatment of pain is palliative. In each instance, such method of treatment requires administering to an animal in need of such treatment an amount of a compound of the present invention that is therapeutically effective in achieving said treatment. In one embodiment, the amount of such compound is the amount that is effective to block sodium channels in vivo.
- Chronic pain includes, but is not limited to, inflammatory pain, postoperative pain, cancer pain, osteoarthritis pain associated with metastatic cancer, trigeminal neuralgia, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, burn pain, and other forms of neuralgia, neuropathic, and idiopathic pain syndromes.
- the inflammatory process is a complex series of biochemical and cellular events activated in response to tissue injury or the presence of foreign substances (Levine, Inflammatory Pain, In: Textbook of Pain, Wall and Melzack eds., 3 rd ed., 1994). Inflammation often occurs at the site of injured tissue, or foreign material, and contributes to the process of tissue repair and healing.
- the cardinal signs of inflammation include erythema (redness), heat, edema (swelling), pain and loss of function (ibid.).
- the majority of patients with inflammatory pain do not experience pain continually, but rather experience enhanced pain when the inflamed site is moved or touched. Inflammatory pain includes, but is not limited to, that associated with osteoarthritis and rheumatoid arthritis.
- Chronic neuropathic pain is a heterogenous disease state with an unclear etiology.
- the pain can be mediated by multiple mechanisms. This type of pain generally arises from injury to the peripheral or central nervous tissue.
- the syndromes include pain associated with spinal cord injury, multiple sclerosis, post-herpetic neuralgia, trigeminal neuralgia, phantom pain, causalgia, and reflex sympathetic dystrophy and lower back pain.
- Chronic pain is different from acute pain in that patients suffer the abnormal pain sensations that can be described as spontaneous pain, continuous superficial burning and/or deep aching pain.
- the pain can be evoked by heat-, cold-, and mechano-hyperalgesia or by heat-, cold-, or mechano-allodynia.
- Neuropathic pain can be caused by injury or infection of peripheral sensory nerves. It includes, but is not limited to, pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies. Stroke (spinal or brain) and spinal cord injury can also induce neuropathic pain. Cancer- related neuropathic pain results from tumor growth compression of adjacent nerves, brain, or spinal cord. In addition, cancer treatments, including chemotherapy and radiation therapy, can also cause nerve injury. Neuropathic pain includes but is not limited to pain caused by nerve injury such as, for example, the pain from which diabetics suffer.
- the present invention is also directed to the use of a compound represented by any of defined Formulae I-XXXIII, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, in the manufacture of a medicament for treating a disorder responsive to the blockade of sodium channels (e.g., any of the disorders listed above) in an animal suffering from said disorder.
- a disorder responsive to the blockade of sodium channels e.g., any of the disorders listed above
- the present invention is also directed to the use of a compound represented by any of defined Formulae I-XXXIII, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, in the manufacture of a medicament, in particular a medicament for modulating sodium channels, in an animal in need thereof.
- R 5a and R 5b are H
- Compounds of Formulae XXI or XXII, wherein E is hydrogen and A 1 is optionally substituted aryl or optionally substituted heteroaryl, can be prepared according to General Scheme 4.
- Compounds of the present invention were assessed by sodium mobilization and/or electrophysiological assays for sodium channel blocker activity.
- One aspect of the present invention is based on the use of the compounds herein described as sodium channel blockers. Based upon this property, compounds of the invention are considered useful in treating a condition or disorder responsive to the blockade of sodium ion channels, e.g., stroke, neuronal damage resulting from head trauma, epilepsy, seizures, general epilepsy with febrile seizures, severe myoclonic epilepsy in infancy, neuronal loss following global and focal ischemia, migraine, familial primary erythromelalgia, paroxysmal extreme pain disorder, cerebellar atrophy, ataxia, dystonia, tremor, mental retardation, autism, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), manic depression, tinnitus, myotonia, a movement disorder, cardiac arrhythmia
- the present invention is directed to compounds of Formulae I-XXXIII that are blockers of sodium channels.
- those compounds having useful sodium channel blocking properties exhibit an IC 50 for Na v l .l, Na v 1.2, Na v 1.3, Na v 1.4, Na v 1.5, Na v 1.6, Na v 1.7, Na v 1.8, and/or Na v 1.9 of about 100 ⁇ or less, e.g., about 50 ⁇ or less, about 10 ⁇ or less, about 5 ⁇ or less, or about 1 ⁇ or less, in sodium mobilization and/or electrophysiological assays.
- Compounds of the Invention exhibit an IC 50 for Na v 1.7 of 100 ⁇ or less, about 50 ⁇ or less, about 10 ⁇ or less, about 5 ⁇ or less, about 1 ⁇ or less, about 0.5 ⁇ or less, or about 0.1 ⁇ or less.
- Compounds of the Invention can be tested for their Na + channel blocking activity using methods known in the art and by the following fluorescence imaging and electrophysiological in vitro assays and/or in vivo assays. In Vitro Assay Protocols
- Recombinant Na v 1.7 Cell Line In vitro assays were performed in a recombinant cell line expressing cDNA encoding the alpha subunit (Na v 1.7, SCN9a, PN1, NE) of human Na v 1.7 (Accession No. NM_002977). The cell line was provided by investigators at Yale University (Cummins et al, J. Neurosci. 18(23): 9607-9619 (1998)). For dominant selection of the Na v 1.7-expressing clones, the expression plasmid co-expressed the neomycin resistance gene.
- the cell line was constructed in the human embryonic kidney cell line, HEK293, under the influence of the CMV major late promoter, and stable clones were selected using limiting dilution cloning and antibiotic selection using the neomycin analogue, G418. Recombinant beta and gamma subunits were not introduced into this cell line. Additional cell lines expressing recombinant Na v 1.7 cloned from other species can also be used, alone or in combination with various beta subunits, gamma subunits or chaperones.
- Non-recombinant Cell Lines Expressing Native Na v l. 7 can be performed in a cell line expressing native, non- recombinant Na v 1.7, such as the ND7 mouse neuroblastoma X rat dorsal root ganglion (DRG) hybrid cell line ND7/23, available from the European Cell Culture Collection (Cat. No. 92090903, Salisbury, Wiltshire, United Kingdom).
- the assays can also be performed in other cell lines expressing native, non-recombinant Na v 1.7, from various species, or in cultures of fresh or preserved sensory neurons, such as dorsal root ganglion (DRG) cells, isolated from various species.
- DRG dorsal root ganglion
- Primary screens or counter-screens of other voltage-gated sodium channels can also be performed, and the cell lines can be constructed using methods known in the art, purchased from collaborators or commercial establishments, and they can express either recombinant or native channels.
- the primary counter-screen is for one of the central neuronal sodium channels, Nayl .2 (rBIIa), expressed in HEK293 host cells (Ilyin et al, Br. J. Pharmacol. 744:801-812 (2005)). Pharmacological profiling for these counter-screens is carried out under conditions similar to the primary or alternative Na v l .7 assays described below.
- cell culture reagents were purchased from Mediatech of Herndon, VA.
- the recombinant Na v 1.7/HEK293 cells were routinely cultured in growth medium consisting of Dulbecco's minimum essential medium containing 10% fetal bovine serum (FBS, Hyclone, Thermo Fisher Scientific, Logan, UT), 100 U/mL penicillin, 100 ⁇ g/mL streptomycin, 2-4 mM L-glutamine, and 500 mg/mL G418.
- FBS fetal bovine serum
- penicillin 100 ⁇ g/mL streptomycin
- 2-4 mM L-glutamine 500 mg/mL G418.
- the selective antibiotic was omitted, and additional media formulations can be applied as needed.
- the assay buffer was formulated by removing 120 mL from a 1 L bottle of fresh, sterile dH 2 0 (Mediatech, Herndon, VA) and adding 100 mL of 10X HBSS that does not contain Ca ⁇ or Mg ++ (Gibco, Invitrogen, Grand Island, NY) followed by 20 mL of 1.0 M Hepes, pH 7.3 (Fisher Scientific, BP299-100).
- the final buffer consisted of 20 mM Hepes, pH 7.3, 1.261 mM CaCl 2 , 0.493 mM MgCl 2 , 0.407 mM Mg(SO) 4 , 5.33 mM KC1, 0.441 mM KH 2 P0 4 , 137 mM NaCl, 0.336 mM Na 2 HP04 and 0.556 mM D-glucose (Hanks et al, Proc. Soc. Exp. Biol. Med. 77:196 (1949)), and the simple formulation was typically the basic buffer throughout the assay ⁇ i.e., all wash and addition steps).
- CoroNaTM Green AM Net Dye for Primary Fluorescence Assay The fluorescence indicator used in the primary fluorescence assay was the cell permeant version of CoroNaTM Green (Invitrogen, Molecular Probes, Eugene, OR), a dye that emits light in the fluorescence range (Harootunian et al, J. Biol. Chem. 264(32): ⁇ 945S- ⁇ 9467 (1989)). The intensity of this emission, but not the wavelength range, is increased when the dye is exposed to Na ions, which it can bind with partial selectivity.
- Cells expressing Na v 1.7 or other sodium channels were loaded with the CoroNaTM Green dye immediately in advance of the fluorescence assay, and then, after agonist stimulation, the mobilization of Na + ions was detected as the Na + ions flowed from the extracellular fluid into the cytoplasm through the activated sodium channel pores.
- the dye was stored in the dark as a lyophilized powder, and then an aliquot was dissolved immediately before the cell loading procedure, according to the instructions of the manufacturer to a stock concentration of 10 mM in DMSO. It was then diluted in the assay buffer to a 4X concentrated working solution, so that the final concentration of dye in the cell loading buffer was 5 ⁇ .
- a fluorescence indicator that can be used in alternative fluorescence assays is the blue version membrane potential dye (MDS, Molecular Devices, Sunnyvale, CA), a dye that detects changes in molecules following a change in membrane potential. An increase in fluorescence is expected if agonist stimulation provokes a change in membrane potential.
- Cells expressing Na v 1.7 or other sodium channels are incubated with the membrane potential dye 30-60 minutes before the fluorescence assay.
- the KC1 pre- stimulation version of the assay the dye and all other components are washed out immediately before the assay, and the dye is then replaced.
- the dye In the version lacking KC1 pre-stimulation, the dye remains on the cells and is not washed out or replaced. The dye is stored in the dark as a lyophilized powder, and then an aliquot dissolved in assay buffer to form a 20X-concentrated stock solution that can be used for several weeks.
- Agonists In the fluorescence assays, two agonists were used in combination, namely 1) veratridine; and 2) the venom from the yellow scorpion, Leiurus quinquestriatus hebraeus.
- Veratridine is an alkaloid small molecule that facilitates the capture of channel openings by inhibiting inactivation
- the scorpion venom is a natural preparation that includes peptide toxins selective for different subsets of voltage-gated sodium channels. These scorpion toxins inhibit the fast inactivation of their cognate target channels.
- Test compounds were dissolved in DMSO to yield 10 mM stock solutions. The stock solutions were further diluted using DMSO in 1 :3 serial dilution steps with 10 points (10,000 ⁇ , 3,333 ⁇ , 1,111 ⁇ , 370 ⁇ , 123 ⁇ , 41 ⁇ , 14 ⁇ , 4.6 ⁇ , 1.5 ⁇ and 0.5 ⁇ ).
- Compound dilutions were added during the dye-loading and pre-stimulation step, and then again during the fluorescence assay, early in the kinetic read. Compound dilutions were added in duplicate rows across the middle 80 wells of the 96-well plate, whereas the fully stimulated and the fully inhibited controls (positive and negative) were located in the top 4 side wells and the bottom 4 side wells, respectively, on the left and right sides of the assay plate.
- FLIPR ® or FLIPR TETRA® sodium dye assay with KCl and test article pre-incubation Cells were prepared by plating the recombinant HEK293 cells or other host cells expressing either recombinant or non-recombinant, native, Nay 1.7 alpha subunit, alone or in combination with various beta and gamma subunits at a density of -40,000 cells/well into a 96-well black, clear- bottom, PDL-coated plate.
- the assay can be adapted to 384-well or 1,536- well format, if desired, using proportionately less cells and media.
- the plate was then incubated in growth media, with or without selective antibiotic, overnight at 37°C at 5% C0 2 , 95% humidity, in preparation for the assay.
- growth media with or without selective antibiotic, overnight at 37°C at 5% C0 2 , 95% humidity, in preparation for the assay.
- the procedure was very similar, though optimal densities of cells, media and subsequent assay components can be fine-tuned for the particular cell line or isoform.
- the components were added as follows, immediately after the wash step: 1) first, the compound dilutions and controls were added as 4X concentrates in assay buffer at 50 ⁇ ,/well; 2) CoroNaTM Green AM dye was diluted from the stock solution to 20 ⁇ in assay buffer (4X concentrate) and added to the plate at 50 ⁇ / ⁇ ; and 3) finally, a solution of 180 mM KC1 (2X) was prepared by diluting a 2M stock solution into assay buffer and the solution was added to the cells at 100 ⁇ /well. The cells were incubated at 25°C in the dark for 30 min. before their fluorescence was measured.
- the plates containing dye-loaded cells were then flicked to remove the pre-incubation components and washed once with 100 ⁇ , ⁇ assay buffer. A 100 ⁇ , ⁇ aliquot of assay buffer was added back to the plate, and the real-time assay was commenced.
- Results were expressed in relative fluorescence units (RFU) and can be determined by using the maximum signal during the latter part of the stimulation; or the maximum minus the minimum during the whole agonist stimulation period; or by taking the area under the curve for the whole stimulation period.
- the assay can be performed as a screening assay as well with the test articles present in standard amounts (e.g., 10 ⁇ ) in only one or two wells of a multi-well plate during the primary screen. Hits in this screen were typically profiled more exhaustively (multiple times), subjected to dose- response or competition assays and tested in counter screens against other voltage-gate sodium channels or other biologically relevant target molecules.
- FLIPR ® or FLIPR TETRA® membrane potential assay with KCl and test article pre-incubation Cells are prepared by plating the recombinant HEK293 cells or other host cells expressing either recombinant or non- recombinant, native, Nay 1.7 alpha subunit, alone or in combination with various beta and gamma subunits at a density of -40,000 cells/well into a 96- well black, clear-bottom, PDL-coated plate.
- the assay can be adapted to 384-well or 1,536-well format, if desired, using proportionately less cells and media.
- the plate is then incubated in growth media, with or without selective antibiotic, overnight at 37°C at 5% C0 2 , 95% humidity, in preparation for the assay (see, e.g., Benjamin et. al., J. Biomol. Screen 10(4):365-373 (2005)).
- the assay protocol is similar, though optimal densities of cells, media and subsequent assay components can be fine-tuned for the particular cell line or sodium channel isoform being tested.
- the media is flicked from the cells and the wells are washed once with 50 ⁇ , ⁇ assay buffer (IX Hank's balanced salt solution without sodium bicarbonate or phenol red, 20 mM Hepes, pH 7.3) and then pre-incubated with the test articles, the membrane potential dye (for cell loading), and the KCl for re-polarization and synchronization of the channels in the entire population of cells.
- 50 ⁇ , ⁇ assay buffer IX Hank's balanced salt solution without sodium bicarbonate or phenol red, 20 mM Hepes, pH 7.3
- the components are added as follows, immediately after the wash step: 1) first, the compound dilutions and controls are added as 4X concentrates in assay buffer at 50 ⁇ , ⁇ ; 2) membrane potential dye is diluted from the stock solution in assay buffer (4X concentrate) and added to the plate at 50 ⁇ ,/ ⁇ ; and 3) finally, a solution of 180 mM KC1 (2X) is prepared by diluting a 2M stock solution into assay buffer and the solution added to the cells at 100 ⁇ , ⁇ . The cells are incubated at 37°C in the dark for 30-60 min. before their fluorescence is measured.
- the plates containing dye-loaded cells are then flicked to remove the pre-incubation components and washed once with 50 ⁇ assay buffer. A 50 ⁇ ⁇ aliquot of membrane potential dye is added back to the plate, and the real-time assay is commenced.
- the additions of the compounds (first) and then the channel activators (later) in this are performed on the fluorescence plate reader and the results, expressed as relative fluorescence units (RFU), are captured by means of camera shots every 1-3 sec, then displayed in real-time and stored. Generally, there is a 15 sec. base line, with camera shots taken every 1.5 sec, then the test compounds are added, then another 120 sec. baseline is conducted, with camera shots taken every 3 se ; and finally, the agonist solution (containing veratridine and scorpion venom) is added. The amplitude of fluorescence increase, resulting from the detection of membrane potential change, is captured for -120 sec. thereafter. Results are expressed in relative fluorescence units (RFU) and can be determined by using the maximum signal during the latter part of the stimulation; or the maximum minus the minimum during the whole stimulation period; or by taking the area under the curve for the whole stimulation period.
- REU relative fluorescence units
- the assay can be performed as a screening assay as well with the test articles present in standard amounts (e.g., 10 ⁇ ) in only one or two wells of a multi-well plate during the primary screen. Hits in this screen are typically profiled more exhaustively (multiple times), subjected to dose-response or competition assays and tested in counter screens against other voltage-gate sodium channels or other biologically relevant target molecules.
- FLIPR ® or FLIPR TETRA® sodium dye assay without KCl and test article pre-incubation Cells are prepared by plating the recombinant
- the assay can be adapted to 384-well or 1,536-well format, if desired, using proportionately less cells and media.
- the plate is then incubated in growth media, with or without selective antibiotic, overnight at 37°C at 5% C0 2 , 95% humidity, in preparation for the assay.
- the procedure is very similar, though optimal densities of cells, media and subsequent assay components can be fine-tuned for the particular cell line or isoform.
- 96-well plate (50 ⁇ ), from a freshly diluted sample of the stock (now at 4X concentration) in the assay buffer. The cells are incubated at 37°C in the dark for 30-60 min. before their fluorescence is measured. [0306] In this standard membrane potential assay, the 96-well plate containing dye-loaded cells is then loaded directly onto the plate reader without aspirating the dye solution and without any further washing of the cells. The fluorescence of cells is measured using a fluorescence plate reader (FLIPR TETRA ® or FLIPR384®, MDS, Molecular Devices, Sunnyvale, CA).
- the additions of the compounds (first, 50 ⁇ /well from a 4X stock plate) and then the channel activators (later, 100 ⁇ from a 2X stock solution) in this kinetic assay are performed on the fluorescence plate reader and the results, expressed as relative fluorescence units (RFU), are captured by means of camera shots every 1-3 sec, then displayed in real-time and stored. Generally, there is a 15 sec. base line, with camera shots taken every 1.5 sec, then the test compounds are added, then another 120 sec.
- RNU relative fluorescence units
- results are expressed in relative fluorescence units (RFU) and can be determined by using the maximum signal during the latter part of the stimulation; or the maximum minus the minimum during the whole stimulation period; or by taking the area under the curve for the whole stimulation period.
- REU relative fluorescence units
- the assay can be performed as a screening assay as well, with the test articles present in standard amounts (e.g. 10 ⁇ ) in only one or two wells of a multi-well plate during the primary screen. Hits in this screen are typically profiled more exhaustively (multiple times), subjected to dose-response or competition assays and tested in counter screens against other voltage-gate sodium channels or other biologically relevant target molecules.
- Cells The hNa v 1.7 expressing HEK-293 cells were plated on 35 mm culture dishes pre-coated with poly-D-lysine in standard DMEM culture media (Mediatech, Inc., Herndon, VA) and incubated in a 5% C0 2 incubator at 37°C. Cultured cells were used approximately 12 - 48 hours after plating.
- standard DMEM culture media Mediatech, Inc., Herndon, VA
- Electrophysiology On the day of experimentation, the 35 mm dish was placed on the stage of an inverted microscope equipped with a perfusion system that continuously perfuses the culture dish with fresh recording media.
- a gravity driven superfusion system was used to apply test solutions directly to the cell under evaluation.
- This system consists of an array of glass pipette glass connected to a motorized horizontal translator. The outlet of the shooter was positioned approximately 100 ⁇ from the cell of interest.
- Voltage protocols After establishing the whole-cell configuration in voltage clamp mode, two voltage protocols were run to establish: 1) the holding potential; and 2) the test potential for each cell.
- Resting block To determine a membrane potential at which the majority of channels are in the resting state, a standard steady-state inactivation (SSIN) protocol was run using 100 ms prepulses x 10 mV depolarizing steps. The holding potential for testing resting block (Vhi) was 20 mV more hyperpolarized than the first potential where inactivation was observed with the inactivation protocol.
- SSIN steady-state inactivation
- the compound testing protocol was a series of 10ms depolarizations from the Vhi (determined from the SSIN) to the Vt (determined from the I-V protocol) repeated every 10-15 seconds. After a stable baseline was established, a high concentration of a test compound (highest concentration solubility permits or that which provides ⁇ 50% block) was applied and block of the current assessed. Washout of the compound was attempted by superfusing with control solution once steady-state block was observed. The fractional response was calculated as follows:
- K r [drug]* ⁇ FR/( ⁇ -FR) ⁇
- [drug] is the concentration of a drug.
- [drug] is the concentration of a drug.
- K i (i-h ) / ((i/K app ) - (h ⁇ r )).
- the voltage clamp protocol to examine hNa v 1.7 currents was as follows. First, the standard current-voltage relationship was tested by pulsing the cell from the holding voltage (V h ) of -120 mV by a series of 5 msec long square-shaped test pulses incrementing in +10 mV steps over the membrane voltage range of -90 mV to + 60 mV at the pace of stimulation of 0.5 Hz. This procedure determines the voltage that elicits the maximal current (V max ).
- V h was re-set to -120 mV and a steady-state inactivation (SSIN) curve was taken by the standard double-pulse protocol: 100 ms depolarizing pre-pulse was incremented in steps of +10 mV (voltage range from -90mV to 0 mV) immediately followed by the 5ms long test pulse to -10 mV at the pace of stimulation of 0.2 Hz. This procedure determines the voltage of full inactivation (Vfuii).
- the cell was repeatedly stimulated with the following protocol, first in the absence of the test compound then in its presence.
- the protocol consisted of depolarizing the cell from the holding potential of -120 mV to the V ⁇ H value for 4.5 seconds then repolanzing the cell to the holding potential for 10 ms before applying the test pulse to the V m ax for 5 ms.
- the amount of inhibition produced by the test compound was determined by comparing the current amplitude elicited by the test pulse in the absence and presence of the compound.
- Compounds were prepared first as series of stock solutions in DMSO and then dissolved in external solution; DMSO content in final dilutions did not exceed 0.3%. At this concentration, DMSO did not affect sodium currents. Vehicle solution used to establish base line was also contacting 0.3% DMSO.
- mice Male Swiss Webster NIH mice (20-30 g; Harlan, San Diego, CA) can be used in all experiments. Food is withdrawn on the day of experiment. Mice are placed in Plexiglass jars for at least 1 hour to acclimate to the environment. Following the acclimation period, mice are weighed and given either the compound of interest administered i.p. or p.o., or the appropriate volume of vehicle (for example, 10 % Tween-80 or 0.9 % saline, and other pharmaceutically acceptable vehicles) as control.
- vehicle for example, 10 % Tween-80 or 0.9 % saline, and other pharmaceutically acceptable vehicles
- mice Fifteen minutes after the i.p. dosing, and 30 minutes after the p.o. dosing mice are injected with formalin (20 ⁇ , of 5% formaldehyde solution in saline) into the dorsal surface of the right hind paw. Mice are transferred to the Plexiglass jars and monitored for the amount of time spent licking or biting the injected paw.
- Periods of licking and biting are recorded in 5 -minute intervals for 1 hour after the formalin injection. All experiments are done in a blinded manner during the light cycle. The early phase of the formalin response is measured as licking / biting between 0-5 minutes, and the late phase is measured from 15-50 minutes. Differences between vehicle and drug treated groups can be analyzed by one-way analysis of variance (ANOVA). A P value ⁇ 0.05 is considered significant. Compounds are considered to be efficacious for treating acute and chronic pain if they have activity in blocking both the early and second phase of formalin-induced paw-licking activity. In Vivo Assays for Inflammatory or Neuropathic Pain
- Test Animals Each experiment uses rats weighing between 200-260 g at the start of the experiment. The rats are group-housed and have free access to food and water at all times, except prior to oral administration of a test compound when food is removed for 16 hours before dosing. A control group acts as a comparison to rats treated with a compound of Formulae I-
- control group is administered the carrier as used for the test compound.
- the volume of carrier administered to the control group is the same as the volume of carrier and test compound administered to the test group.
- FCA Freund's complete adjuvant
- the animal is assessed for response to noxious mechanical stimuli by determining the paw withdrawal threshold (PWT), or to noxious thermal stimuli by determining the paw withdrawal latency (PWL), as described below.
- Rats are then administered a single injection of either a test compound or 30 mg/kg of a positive control compound (indomethacin).
- Responses to noxious mechanical or thermal stimuli are then determined 1, 3, 5 and 24 hours post administration (admin).
- Percentage reversal of hyperalgesia for each animal is defined as:
- the partial sciatic nerve ligation model of neuropathic pain was used to produce neuropathic hyperalgesia in rats (Seltzer et al, Pain 43:205-218 (1990)). Partial ligation of the left sciatic nerve was performed under inhalation anesthesia, e.g., isoflurane/0 2 . Following induction of anesthesia, the left thigh of the rat was shaved and the sciatic nerve exposed at high thigh level through a small incision and was carefully cleared of surrounding connective tissues at a site near the trocanther just distal to the point at which the posterior biceps semitendinosus nerve branches off of the common sciatic nerve.
- inhalation anesthesia e.g., isoflurane/0 2
- a 7-0 silk suture was inserted into the nerve, e.g., with a 3/8 curved, reversed-cutting mini-needle, and tightly ligated so that the dorsal 1/3 to 1 ⁇ 2 of the nerve thickness was held within the ligature.
- the wound was closed, e.g., with a single muscle suture (4-0 nylon (Vicryl)) and vetbond tissue glue. Following surgery, the wound area was dusted with antibiotic powder. Sham-treated rats undergo an identical surgical procedure except that the sciatic nerve is not manipulated. Following surgery, animals were weighed and placed on a warm pad until they recovered from anesthesia. Animals were then returned to their home cages until behavioral testing began.
- Cpd No. 63 (vehicle: 10% Tween 80 in water) did not produce a statistically significant increase in paw withdrawal threshold in the Seltzer model at 30 mg/kg p.o.
- the spinal nerve ligation model of neuropathic pain is used to produce mechanical hyperalgesia, thermal hyperalgesia and tactile allodynia in rats.
- Surgery is performed under isoflurane/0 2 inhalation anesthesia.
- a 3 cm incision is made and the left paraspinal muscles are separated from the spinous process at the L 4 - S 2 levels.
- the L 6 transverse process is carefully removed with a pair of small rongeurs to identify visually the L 4 - L 6 spinal nerves.
- the left L 5 (or L 5 and L 6 ) spinal nerve(s) is (are) isolated and tightly ligated with silk thread.
- a complete hemostasis is confirmed and the wound is sutured using nonabsorbable sutures, such as nylon sutures or stainless steel staples.
- Sham- treated rats undergo an identical surgical procedure except that the spinal nerve(s) is (are) not manipulated.
- animals are weighed, administered a subcutaneous (s.c.) injection of saline or ringers lactate, the wound area is dusted with antibiotic powder and they are kept on a warm pad until they recover from the anesthesia. Animals are then returned to their home cages until behavioral testing begins.
- the animals are assessed for response to noxious mechanical stimuli by determining PWT, as described below, prior to surgery (baseline), then immediately prior to and 1, 3, and 5 hours after being administered a compound of Formulae I-XXXIII for the left rear paw of the animal.
- the animals can also be assessed for response to noxious thermal stimuli or for tactile allodynia, as described below.
- the Chung model for neuropathic pain is described in Kim et at, Pain 50(3):355- 363 (1992).
- Tactile Allodynia Sensitivity to non-noxious mechanical stimuli can be measured in animals to assess tactile allodynia. Rats are transferred to an elevated testing cage with a wire mesh floor and allowed to acclimate for five to ten minutes. A series of von Frey monofilaments are applied to the plantar surface of the hindpaw to determine the animal's withdrawal threshold. The first filament used possesses a buckling weight of 9.1 gms (.96 log value) and is applied up to five times to see if it elicits a withdrawal response. If the animal has a withdrawal response, then the next lightest filament in the series would be applied up to five times to determine if it also could elicit a response.
- Mechanical Hyperalgesia Sensitivity to noxious mechanical stimuli can be measured in animals using the paw pressure test to assess mechanical hyperalgesia.
- PWT hind paw withdrawal thresholds
- the rat's paw is placed on a small platform, and weight is applied in a graded manner up to a maximum of 250 grams. The endpoint is taken as the weight at which the paw is completely withdrawn. PWT is determined once for each rat at each time point.
- PWT can be measured only in the injured paw, or in both the injured and non-injured paw.
- mechanical hyperalgesia associated with nerve injury induced pain can be assessed in rats. Rats are tested prior to surgery to determine a baseline, or normal, PWT. Rats are tested again 2 to 3 weeks post-surgery, prior to, and at different times after (e.g. 1, 3, 5 and 24 hr) drug administration. An increase in PWT following drug administration indicates that the test compound reduces mechanical hyperalgesia.
- the compounds of the present invention of the present invention can be tested for in vivo anticonvulsant activity after i.v., p.o., or i.p. injection using any of a number of anticonvulsant tests in mice, including the maximum electroshock seizure test (MES).
- MES maximum electroshock seizure test
- a tonic seizure is defined as a hindlimb extension in excess of 90 degrees from the plane of the body. Results can be treated in a quantal manner.
- a Compound of the Invention can be administered to a mammal in the form of a raw chemical without any other components present, the compound is preferably administered as part of a pharmaceutical composition containing the compound combined with a suitable pharmaceutically acceptable carrier.
- a suitable pharmaceutically acceptable carrier can be selected from pharmaceutically acceptable excipients and auxiliaries.
- compositions within the scope of the present invention include all compositions where a Compound of the Invention is combined with a pharmaceutically acceptable carrier.
- the compound is present in the composition in an amount that is effective to achieve its intended therapeutic purpose. While individual needs may vary, a determination of optimal ranges of effective amounts of each compound is within the skill of the art.
- a compound can be administered to a mammal, e.g., a human, orally at a dose of from about 0.0025 to about 1500 mg per kg body weight of the mammal, or an equivalent amount of a pharmaceutically acceptable salt, prodrug, or solvate thereof, per day to treat the particular disorder.
- a useful oral dose of a Compound of the Invention administered to a mammal is from about 0.0025 to about 50 mg per kg body weight of the mammal, or an equivalent amount of the pharmaceutically acceptable salt, prodrug, or solvate thereof.
- the dose is typically about one-half of the oral dose.
- a unit oral dose may comprise from about 0.01 to about 50 mg, and preferably about 0.1 to about 10 mg, of the compound.
- the unit dose can be administered one or more times daily, e.g., as one or more tablets or capsules, each containing from about 0.01 to about 50 mg of the compound, or an equivalent amount of a pharmaceutically acceptable salt, prodrug or solvate thereof.
- a pharmaceutical composition of the present invention can be administered to any animal that may experience the beneficial effects of a compound of the present invention.
- animals e.g., humans and companion animals, although the invention is not intended to be so limited.
- a pharmaceutical composition of the present invention can be administered by any means that achieves its intended purpose.
- administration can be by the oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, intranasal, transmucosal, rectal, intravaginal or buccal route, or by inhalation.
- the dosage administered and route of administration will vary, depending upon the circumstances of the particular subject, and taking into account such factors as age, gender, health, and weight of the recipient, condition or disorder to be treated, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- a pharmaceutical composition of the present invention can be administered orally and is formulated into tablets, dragees, capsules or an oral liquid preparation.
- the oral formulation comprises extruded multiparticulates comprising the compound of the invention.
- a pharmaceutical composition of the present invention can be administered rectally, and is formulated in suppositories.
- a pharmaceutical composition of the present invention can be administered by injection.
- a pharmaceutical composition of the present invention can be administered transdermally.
- composition of the present invention can be administered by inhalation or by intranasal or transmucosal administration.
- a pharmaceutical composition of the present invention can be administered by the intravaginal route.
- a pharmaceutical composition of the present invention can contain from about 0.01 to 99 percent by weight, and preferably from about 0.25 to 75 percent by weight, of active compound(s).
- a method of the present invention such as a method for treating a disorder responsive to the blockade of sodium channels in an animal in need thereof, can further comprise administering a second therapeutic agent to the animal in combination with a compound of the present invention.
- the other therapeutic agent is administered in an effective amount.
- a compound of the present invention i.e., the first therapeutic agent
- the second therapeutic agent can be used to treat a disorder or condition that is different from the disorder or condition for which the first therapeutic agent is being administered, and which disorder or condition may or may not be a condition or disorder as defined herein.
- a compound of the present invention is administered concurrently with a second therapeutic agent; for example, a single composition comprising both an effective amount of a compound of any of Formulae I-XXXIII, and an effective amount of the second therapeutic agent can be administered.
- the present invention further provides a pharmaceutical composition comprising a combination of a compound of the present invention, the second therapeutic agent, and a pharmaceutically acceptable carrier.
- a first pharmaceutical composition comprising an effective amount of a compound of any of Formulae I-XXXIII and a second pharmaceutical composition comprising an effective amount of the second therapeutic agent can be concurrently administered.
- an effective amount of a compound of the present invention is administered prior or subsequent to administration of an effective amount of the second therapeutic agent.
- the compound of the present invention is administered while the second therapeutic agent exerts its therapeutic effect, or the second therapeutic agent is administered while the compound of the present invention exerts its therapeutic effect for treating a disorder or condition.
- the second therapeutic agent can be an opioid agonist, a non-opioid analgesic, a non-steroidal anti-inflammatory agent, an antimigraine agent, a Cox-II inhibitor, a ⁇ -adrenergic blocker, an anticonvulsant, an antidepressant, an anticancer agent, an agent for treating addictive disorder, an agent for treating Parkinson's disease and parkinsonism, an agent for treating anxiety, an agent for treating epilepsy, an agent for treating a seizure, an agent for treating a stroke, an agent for treating a pruritic condition, an agent for treating psychosis, an agent for treating ALS, an agent for treating a cognitive disorder, an agent for treating a migraine, an agent for treating vomiting, an agent for treating dyskinesia, or an agent for treating depression, or a mixture thereof.
- Examples of useful opioid agonists include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamo hone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lof
- the opioid agonist is selected from codeine, hydromorphone, hydrocodone, oxycodone, dihydrocodeine, dihydromorphine, morphine, tramadol, oxymorphone, pharmaceutically acceptable salts thereof, and mixtures thereof.
- non-opioid analgesics include non-steroidal antiinflammatory agents, such as aspirin, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfen
- non-opioid analgesics include the following, non limiting, chemical classes of analgesic, antipyretic, nonsteroidal antiinflammatory drugs: salicylic acid derivatives, including aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, salicylsalicylic acid, sulfasalazine, and olsalazin; para aminophennol derivatives including acetaminophen and phenacetin; indole and indene acetic acids, including indomethacin, sulindac, and etodolac; heteroaryl acetic acids, including tolmetin, diclofenac, and ketorolac; anthranilic acids (fenamates), including mefenamic acid, and meclofenamic acid; enolic acids, including oxicams (piroxicam, tenoxicam), and pyrazolidinediones (phenylbutylbut
- Cox- II inhibitors and 5 -lipoxygenase inhibitors, as well as combinations thereof, are described in U.S. Patent No. 6,136,839, which is hereby incorporated by reference in its entirety.
- useful Cox II inhibitors include, but are not limited to, rofecoxib and celecoxib.
- useful antimigraine agents include, but are not limited to, alpiropride, bromocriptine, dihydroergotamine, dolasetron, ergocornine, ergocorninine, ergocryptine, ergonovine, ergot, ergotamine, flumedroxone acetate, fonazine, ketanserin, lisuride, lomerizine, methylergonovine, methysergide, metoprolol, naratriptan, oxetorone, pizotyline, propranolol, risperidone, rizatriptan, sumatriptan, timolol, trazodone, zolmitriptan, and mixtures thereof.
- Examples of useful ⁇ -adrenergic blockers include, but are not limited to, acebutolol, alprenolol, amosulabol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bufuralol, bunitrolol, bupranolol, butidrine hydrochloride, butofilolol, carazolol, carteolol, carvedilol, celiprolol, cetamolol, cloranolol, dilevalol, epanolol, esmolol, indenolol, labetalol, levobunolol, mepindolol, metipranolol, metoprolol
- Examples of useful anticonvulsants include, but are not limited to, acetylpheneturide, albutoin, aloxidone, aminoglutethimide, 4-amino-3- hydroxybutyric acid, atrolactamide, beclamide, buramate, calcium bromide, carbamazepine, cinromide, clomethiazole, clonazepam, decimemide, diethadione, dimethadione, doxenitroin, eterobarb, ethadione, ethosuximide, ethotoin, felbamate, fluoresone, gabapentin, 5-hydroxytryptophan, lamotrigine, magnesium bromide, magnesium sulfate, mephenytoin, mephobarbital, metharbital, methetoin, methsuximide, 5-methyl-5-(3- phenanthryl)-hydantoin, 3-methyl-5-phenylhydantoin,
- Examples of useful antidepressants include, but are not limited to, binedaline, caroxazone, citalopram, (S)-citalopram, dimethazan, fencamine, indalpine, indeloxazine hydrocholoride, nefopam, nomifensine, oxitriptan, oxypertine, paroxetine, sertraline, thiazesim, trazodone, benmoxine, iproclozide, iproniazid, isocarboxazid, nialamide, octamoxin, phenelzine, cotinine, rolicyprine, rolipram, maprotiline, metralindole, mianserin, mirtazepine, adinazolam, amitriptyline, amitriptylinoxide, amoxapine, butriptyline, clomipramine, demexip
- Examples of useful anticancer agents include, but are not limited to, acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chloram
- Therapeutic agents useful for treating an addictive disorder include, but are not limited to, methadone, desipramine, amantadine, fluoxetine, buprenorphine, an opiate agonist, 3-phenoxypyridine, or a serotonin antagonist.
- Examples of useful therapeutic agents for treating Parkinson's disease and parkinsonism include, but are not limited to, carbidopa/levodopa, pergolide, bromocriptine, ropinirole, pramipexole, entacapone, tolcapone, selegiline, amantadine, and trihexyphenidyl hydrochloride.
- Examples of useful therapeutic agents for treating anxiety include, but are not limited to, benzodiazepines, such as alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, estazolam, fiumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, and triazolam; non-benzodiazepine agents, such as buspirone, gepirone, ipsapirone, tiospirone, zolpicone, Zolpidem, and zaleplon; tranquilizers, such as barbituates, e.g., amobarbital, aprobarbital, butabarbital, butalbital,
- Examples of useful therapeutic agents for treating epilepsy or seizure include, but are not limited to, carbamazepine, ethosuximide, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone, valproic acid, trimethadione, benzodiazepines, gamma-vinyl GABA, acetazolamide, and felbamate.
- Examples of useful therapeutic agents for treating stroke include, but are not limited to, anticoagulants such as heparin, agents that break up clots such as streptokinase or tissue plasminogen activator, agents that reduce swelling such as mannitol or corticosteroids, and acetylsalicylic acid.
- anticoagulants such as heparin
- agents that break up clots such as streptokinase or tissue plasminogen activator
- agents that reduce swelling such as mannitol or corticosteroids
- acetylsalicylic acid acetylsalicylic acid
- Examples of useful therapeutic agents for treating a pruritic condition include, but are not limited to, naltrexone; nalmefene; danazol; tricyclics such as amitriptyline, imipramine, and doxepin; antidepressants such as those given below; menthol; camphor; phenol; pramoxine; capsaicin; tar; steroids; and antihistamines.
- Examples of useful therapeutic agents for treating psychosis include, but are not limited to, phenothiazines such as chlorpromazine hydrochloride, mesoridazine besylate, and thoridazine hydrochloride; thioxanthenes such as chloroprothixene and thiothixene hydrochloride; clozapine; risperidone; olanzapine; quetiapine; quetiapine fumarate; haloperidol; haloperidol decanoate; loxapine succinate; molindone hydrochloride; pimozide; and ziprasidone.
- phenothiazines such as chlorpromazine hydrochloride, mesoridazine besylate, and thoridazine hydrochloride
- thioxanthenes such as chloroprothixene and thiothixene hydrochloride
- clozapine r
- Examples of useful therapeutic agents for treating ALS include, but are not limited to, baclofen, neurotrophic factors, riluzole, tizanidine, benzodiazepines such as clonazepan and dantrolene.
- Examples of useful therapeutic agents for treating cognitive disorders include, but are not limited to, agents for treating dementia such as tacrine; donepezil; ibuprofen; antipsychotic drugs such as thioridazine and haloperidol; and antidepressant drugs such as those given below.
- agents for treating dementia such as tacrine; donepezil; ibuprofen; antipsychotic drugs such as thioridazine and haloperidol; and antidepressant drugs such as those given below.
- Examples of useful therapeutic agents for treating a migraine include, but are not limited to, sumatriptan; methysergide; ergotamine; caffeine; and beta-blockers such as propranolol, verapamil, and divalproex.
- Examples of useful therapeutic agents for treating vomiting include, but are not limited to, 5-HT3 receptor antagonists such as ondansetron, dolasetron, granisetron, and tropisetron; dopamine receptor antagonists such as prochlorperazine, thiethylperazine, chlorpromazine, metoclopramide, and domperidone; glucocorticoids such as dexamethasone; and benzodiazepines such as lorazepam and alprazolam.
- 5-HT3 receptor antagonists such as ondansetron, dolasetron, granisetron, and tropisetron
- dopamine receptor antagonists such as prochlorperazine, thiethylperazine, chlorpromazine, metoclopramide, and domperidone
- glucocorticoids such as dexamethasone
- benzodiazepines such as lorazepam and alprazolam.
- Examples of useful therapeutic agents for treating dyskinesia include, but are not limited to, reserpine and tetrabenazine.
- Examples of useful therapeutic agents for treating depression include, but are not limited to, tricyclic antidepressants such as amitryptyline, amoxapine, bupropion, clomipramine, desipramine, doxepin, imipramine, maprotiline, nefazadone, nortriptyline, protriptyline, trazodone, trimipramine, and venlafaxine; selective serotonin reuptake inhibitors such as citalopram, (S)-citalopram, fluoxetine, fluvoxamine, paroxetine, and setraline; monoamine oxidase inhibitors such as isocarboxazid, pargyline, phenelzine, and tranylcypromine; and psychostimulants such as dextroamphetamine
- a pharmaceutical composition of the present invention is preferably manufactured in a manner which itself will be known in view of the instant disclosure, for example, by means of conventional mixing, granulating, dragee-making, dissolving, extrusion, or lyophilizing processes.
- pharmaceutical compositions for oral use can be obtained by combining the active compound with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
- Suitable excipients include fillers such as saccharides (for example, lactose, sucrose, mannitol or sorbitol), cellulose preparations, calcium phosphates (for example, tricalcium phosphate or calcium hydrogen phosphate), as well as binders such as starch paste (using, for example, maize starch, wheat starch, rice starch, or potato starch), gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
- saccharides for example, lactose, sucrose, mannitol or sorbitol
- cellulose preparations for example, calcium phosphates (for example, tricalcium phosphate or calcium hydrogen phosphate)
- binders such as starch paste (using, for example, maize starch, wheat starch, rice starch, or potato starch), gelatin, tragacanth, methyl cellulose, hydroxypropylmethyl
- one or more disintegrating agents can be added, such as the above-mentioned starches and also carboxymethyl- starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
- Auxiliaries are typically flow-regulating agents and lubricants such as, for example, silica, talc, stearic acid or salts thereof (e.g., magnesium stearate or calcium stearate), and polyethylene glycol.
- Dragee cores are provided with suitable coatings that are resistant to gastric juices.
- concentrated saccharide solutions can be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropymethyl-cellulose phthalate can be used.
- Dye stuffs or pigments can be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
- Examples of other pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, or soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
- the push-fit capsules can contain a compound in the form of granules, which can be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers, or in the form of extruded multiparticulates.
- the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils or liquid paraffin.
- stabilizers can be added.
- Possible pharmaceutical preparations for rectal administration include, for example, suppositories, which consist of a combination of one or more active compounds with a suppository base.
- Suitable suppository bases include natural and synthetic triglycerides, and paraffin hydrocarbons, among others. It is also possible to use gelatin rectal capsules consisting of a combination of active compound with a base material such as, for example, a liquid triglyceride, polyethylene glycol, or paraffin hydrocarbon.
- Suitable formulations for parenteral administration include aqueous solutions of the active compound in a water-soluble form such as, for example, a water-soluble salt, alkaline solution, or acidic solution.
- a suspension of the active compound can be prepared as an oily suspension.
- Suitable lipophilic solvents or vehicles for such as suspension may include fatty oils (for example, sesame oil), synthetic fatty acid esters (for example, ethyl oleate), triglycerides, or a polyethylene glycol such as polyethylene glycol-400 (PEG-400).
- An aqueous suspension may contain one or more substances to increase the viscosity of the suspension, including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
- the suspension may optionally contain stabilizers.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112013006272A BR112013006272A2 (en) | 2010-09-17 | 2011-09-16 | pyridine compounds and their uses |
AU2011303597A AU2011303597A1 (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and the uses thereof |
MX2013003101A MX2013003101A (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and the uses thereof. |
KR1020137009767A KR20130056345A (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and the uses thereof |
CN2011800446318A CN103153955A (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and the uses thereof |
CA2811479A CA2811479A1 (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and the uses thereof |
EP19189601.8A EP3590925B1 (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and the uses thereof |
JP2013528783A JP2013538227A (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and their use |
US13/821,732 US9056832B2 (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and the users thereof |
EP11776851.5A EP2616441B1 (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and the uses thereof |
IL225185A IL225185A0 (en) | 2010-09-17 | 2013-03-12 | Pyridine compounds and the uses thereof |
US14/724,494 US9611222B2 (en) | 2010-09-17 | 2015-05-28 | Pyridine compounds and the uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38413610P | 2010-09-17 | 2010-09-17 | |
US61/384,136 | 2010-09-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/821,732 A-371-Of-International US9056832B2 (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and the users thereof |
US14/724,494 Continuation US9611222B2 (en) | 2010-09-17 | 2015-05-28 | Pyridine compounds and the uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012035421A2 true WO2012035421A2 (en) | 2012-03-22 |
WO2012035421A3 WO2012035421A3 (en) | 2012-09-07 |
Family
ID=44903282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/002172 WO2012035421A2 (en) | 2010-09-17 | 2011-09-16 | Pyridine compounds and the uses thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US9056832B2 (en) |
EP (2) | EP2616441B1 (en) |
JP (1) | JP2013538227A (en) |
KR (1) | KR20130056345A (en) |
CN (1) | CN103153955A (en) |
AR (1) | AR083023A1 (en) |
AU (1) | AU2011303597A1 (en) |
BR (1) | BR112013006272A2 (en) |
CA (1) | CA2811479A1 (en) |
IL (1) | IL225185A0 (en) |
MX (1) | MX2013003101A (en) |
WO (1) | WO2012035421A2 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013072758A1 (en) * | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
US8536186B2 (en) | 2008-08-04 | 2013-09-17 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
WO2014135955A1 (en) * | 2013-03-04 | 2014-09-12 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
WO2014151393A2 (en) * | 2013-03-15 | 2014-09-25 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
US8883785B2 (en) | 2010-01-25 | 2014-11-11 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US9056832B2 (en) | 2010-09-17 | 2015-06-16 | Purdue Pharma L.P. | Pyridine compounds and the users thereof |
WO2015094443A1 (en) | 2013-12-20 | 2015-06-25 | Purdue Pharma L.P. | Pyrimidines and use thereof |
WO2015112801A1 (en) | 2014-01-24 | 2015-07-30 | Purdue Pharma L.P. | Pyridines and pyrimidines and use thereof |
US9107923B2 (en) | 2013-06-27 | 2015-08-18 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9120752B2 (en) | 2010-07-16 | 2015-09-01 | Purdue Pharma, L.P. | Pyridine compounds as sodium channel blockers |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
US9388137B2 (en) | 2011-10-31 | 2016-07-12 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
US9428464B2 (en) | 2011-08-30 | 2016-08-30 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US9624194B2 (en) | 2011-10-31 | 2017-04-18 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
US9718780B2 (en) | 2012-03-16 | 2017-08-01 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
US9763955B2 (en) | 2015-02-19 | 2017-09-19 | Purdue Pharma L.P. | Methods and compositions for decreasing gastric emptying |
US9834543B2 (en) | 2013-12-23 | 2017-12-05 | Purdue Pharma L.P. | Indazoles and use thereof |
US9884865B2 (en) | 2013-08-26 | 2018-02-06 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
US9902726B2 (en) | 2013-12-30 | 2018-02-27 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
US9975854B2 (en) | 2014-05-06 | 2018-05-22 | Purdue Pharma L.P. | Benzomorphan analogs and use thereof |
US9981918B2 (en) | 2011-08-30 | 2018-05-29 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US10131666B2 (en) | 2014-06-13 | 2018-11-20 | Purdue Pharma L.P. | Heterocyclic morphinan derivatives and use thereof |
US10202382B2 (en) | 2014-06-13 | 2019-02-12 | Purdue Pharma L.P. | Azamorphinan derivatives and use thereof |
US10258621B2 (en) | 2014-07-17 | 2019-04-16 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
US10738026B2 (en) | 2014-02-12 | 2020-08-11 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
WO2020161146A1 (en) * | 2019-02-07 | 2020-08-13 | Nouryon Chemicals International B.V. | Process for manufacturing alkyleneamine compounds |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9212139B2 (en) | 2010-06-16 | 2015-12-15 | Purdue Pharma, L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
AR083339A1 (en) | 2010-10-05 | 2013-02-21 | Purdue Pharma Lp | QUINAZOLINE COMPOUNDS AS BLOCKERS OF THE SODIUM CHANNELS |
AU2011346751A1 (en) * | 2010-12-22 | 2013-05-02 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
US9163008B2 (en) | 2011-09-02 | 2015-10-20 | Purdue Pharma, L.P. | Pyrimidines as sodium channel blockers |
WO2014072809A2 (en) | 2012-11-09 | 2014-05-15 | Purdue Pharma L.P. | Benzomorphan analogs and the use thereof |
US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
WO2015048662A2 (en) * | 2013-09-30 | 2015-04-02 | X-Rx Discovery, Inc. | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
US9695144B2 (en) | 2013-12-23 | 2017-07-04 | Purdue Pharma L.P. | Dibenzazepine derivatives and use thereof |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
US10745402B2 (en) | 2017-01-02 | 2020-08-18 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
CN108358966B (en) * | 2018-03-05 | 2020-04-28 | 南京工业大学 | Targeting-mitochondrial function enhancing drug Mito-VB3 and preparation method and application thereof |
US11008302B2 (en) * | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136839A (en) | 1995-06-12 | 2000-10-24 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4697012A (en) * | 1984-07-25 | 1987-09-29 | Merck & Co., Inc. | Morpholino pyridyl thiazole compound |
DE3922735A1 (en) * | 1989-07-11 | 1991-01-24 | Hoechst Ag | AMINOPYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE AGENTS CONTAINING THEY AND THEIR USE AS FUNGICIDES |
US5639770A (en) * | 1992-05-29 | 1997-06-17 | Otsuka Pharmaceutical Co., Ltd. | Thiazole derivatives |
JP3385387B2 (en) * | 1992-05-29 | 2003-03-10 | 大塚製薬株式会社 | Thiazole derivatives |
WO1993024472A1 (en) * | 1992-05-29 | 1993-12-09 | Otsuka Pharmaceutical Co., Ltd. | Thiazole derivative |
AU693475B2 (en) * | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
WO1995009851A1 (en) * | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
DE4337322A1 (en) * | 1993-11-02 | 1995-05-04 | Basf Ag | Pyride-N-oxide substituted salicylaldehyde or salicylic acid derivatives, processes for their preparation and their use as herbicides |
AT400845B (en) | 1993-12-06 | 1996-03-25 | Chem Pharm Forsch Gmbh | NEW THIENOTHIAZINE DERIVATIVES, A METHOD FOR THEIR PRODUCTION AND THEIR USE |
DE4430638A1 (en) * | 1994-08-29 | 1996-03-07 | Bayer Ag | Use of substituted 4-phenyl-6-amino-nicotinic acid derivatives as a medicament |
IL132522A0 (en) | 1997-04-22 | 2001-03-19 | Cocensys Inc | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and pharmaceutical compositions containing the same |
CN101328186A (en) | 1997-11-11 | 2008-12-24 | 辉瑞产品公司 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
CA2310664C (en) | 1997-11-21 | 2008-03-11 | Euro-Celtique S.A. | Substituted 2-aminoacetamides and the use thereof |
US6281211B1 (en) | 1999-02-04 | 2001-08-28 | Euro-Celtique S.A. | Substituted semicarbazides and the use thereof |
RU2001129155A (en) | 1999-03-26 | 2003-08-10 | Еро-Сельтик С.А. (Lu) | Compounds with aryl substituents (options), pharmaceutical composition and method for treating a disorder sensitive to blockade of sodium channels in a mammal, method for treating, preventing various diseases or decreasing the rate of death or loss of neurons (options), method for alleviating or preventing epileptic seizures in an animal (options ), the compound is a radioactive ligand for the binding site in the sodium channel |
EP1169060B1 (en) | 1999-04-09 | 2005-08-31 | Euro-Celtique S.A. | Sodium channel blocker compositions and the use thereof |
AR029489A1 (en) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | PIRIDINES, PYRIMIDINES, PIRAZINAS, TRIAZINES REPLACED BY ARILO, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
HU229371B1 (en) | 2000-03-24 | 2013-11-28 | Euro Celtique Sa | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
EP1268427A1 (en) | 2000-03-31 | 2003-01-02 | Cocensys, Inc. | Aminopyridines and their use as anticonvulsants and sodium channel blockers |
HUP0301562A2 (en) * | 2000-06-05 | 2003-12-29 | Dong A Pharm. Co., Ltd. | Novel oxazolidinone derivatives and a process for the preparation thereof and pharmaceutical compositions containing them |
KR20030026979A (en) * | 2000-07-18 | 2003-04-03 | 야마노우치세이야쿠 가부시키가이샤 | Medicine Comprising Dicyanopyridine Derivative |
IL159765A0 (en) | 2001-07-16 | 2004-06-20 | Euro Celtique Sa | Aryl substituted thiazolidinone derivatives and pharmaceutical compositions containing the same |
AR037233A1 (en) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | PIRIDINAS ARIL REPLACED, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT |
AR036873A1 (en) * | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | PIRIDINAS ARIL REPLACED A, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT |
AU2002365892A1 (en) * | 2001-11-30 | 2003-06-17 | Merck & Co., Inc. | Metabotropic glutamate receptor-5 modulators |
CN1646500A (en) | 2002-03-13 | 2005-07-27 | 欧洲凯尔特股份有限公司 | Aryl substituted pyrimidines and the use thereof |
DE60329910D1 (en) | 2002-03-29 | 2009-12-17 | Novartis Vaccines & Diagnostic | SUBSTITUTED BENZAZOLE AND THEIR USE AS RAF KINASE HEMMER |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
BR0313352A (en) | 2002-07-31 | 2005-07-12 | Euro Celtique Sa | Compound, pharmaceutical compositions, method for producing a compound, method for treating, preventing or ameliorating a disorder and method for treating a mammal |
GB0217787D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | C ompounds |
CN1671387A (en) | 2002-07-31 | 2005-09-21 | 欧洲凯尔特股份有限公司 | Aryl substituted hydantoin compounds and their use as sodium channel blockers |
US20040152696A1 (en) | 2002-08-01 | 2004-08-05 | Euro-Celtique S.A. | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
WO2004014844A2 (en) | 2002-08-09 | 2004-02-19 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
PA8578101A1 (en) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS |
SE0203654D0 (en) | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
US20040142978A1 (en) * | 2002-12-12 | 2004-07-22 | Pharmacia Corporation | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 |
US20040142379A1 (en) | 2003-01-16 | 2004-07-22 | Carlsberg Research Laboratory | Affinity fishing for ligands and proteins receptors |
AU2004224392A1 (en) * | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocyles as sodium channel blockers |
CA2521399A1 (en) | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
WO2005014566A1 (en) | 2003-08-07 | 2005-02-17 | Bayer Pharmaceuticals Corporation | Benzofuran derivatives useful for treating hyper-proliferative disorders |
WO2005080393A1 (en) | 2004-02-14 | 2005-09-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JP4902348B2 (en) | 2004-03-04 | 2012-03-21 | キッセイ薬品工業株式会社 | Nitrogen-containing fused ring derivative, pharmaceutical composition containing it, and pharmaceutical use thereof |
WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
JP4894517B2 (en) | 2004-08-27 | 2012-03-14 | アステラス製薬株式会社 | 2-Phenylpyridine derivative |
TW200621251A (en) | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
CN101103016A (en) | 2004-11-18 | 2008-01-09 | 因塞特公司 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same |
US20060281763A1 (en) | 2005-03-25 | 2006-12-14 | Axon Jonathan R | Carboxamide inhibitors of TGFbeta |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
WO2007039146A1 (en) * | 2005-09-23 | 2007-04-12 | Smithkline Beecham Corporation | 4-carboxy pyrazole derivatives as anti-viral agents |
AR056200A1 (en) | 2005-09-27 | 2007-09-26 | Wyeth Corp | TIENO [2,3-B] PIRIDIN-5-CARBONITRILS AS INHIBITORS OF PROTEIN KINASE |
TW200732313A (en) | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
CA2672940A1 (en) * | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
US8207196B2 (en) * | 2007-02-02 | 2012-06-26 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
AR067585A1 (en) | 2007-07-19 | 2009-10-14 | Schering Corp | AMIDAS HETEROCICLICAL COMPOUNDS AS INHIBITORS OF PROTEINCINASE |
CA2695304A1 (en) * | 2007-08-02 | 2009-02-05 | Pfizer Inc. | Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions |
WO2009079412A2 (en) * | 2007-12-14 | 2009-06-25 | Ardea Biosciences Inc. | Reverse transcriptase inhibitors |
TW200940537A (en) * | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
AU2009221583B2 (en) * | 2008-03-05 | 2013-06-20 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
NZ587096A (en) * | 2008-03-26 | 2011-11-25 | Global Alliance For Tb Drug Dev | Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones |
JP2011184298A (en) | 2008-06-02 | 2011-09-22 | Sanwa Kagaku Kenkyusho Co Ltd | Novel compound, and pharmaceutical application thereof |
GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
ES2439767T3 (en) * | 2008-08-01 | 2014-01-24 | Purdue Pharma Lp | Tetrahydropyridinyl and dihydropyrrolyl compounds and use thereof |
US20100041891A1 (en) | 2008-08-12 | 2010-02-18 | Takeda Pharmaceutical Company Limited | Amide compound |
JP5563985B2 (en) * | 2008-10-15 | 2014-07-30 | キッセイ薬品工業株式会社 | Phenylisonicotinic acid derivative and pharmaceutical use thereof |
EP2860178B1 (en) | 2008-10-31 | 2021-01-13 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
CN102216286A (en) * | 2008-11-14 | 2011-10-12 | 拜尔农科股份公司 | Substituted (pyridyl)-azinylamine derivatives as plant protection agents |
BRPI1006128A2 (en) * | 2009-01-12 | 2016-11-01 | Cagen Inc | sulfonamide derivatives |
WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
FI20095302A0 (en) * | 2009-03-24 | 2009-03-24 | Arctic Partners Oy Ab | Luminesenssimääritysmenetelmä |
WO2010138600A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
GEP20146014B (en) | 2009-06-26 | 2014-01-27 | Pfizer | Heterocyclic sulfonamides, usage thereof and their pharmaceutical compositions |
EP2464647B1 (en) * | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
US9212139B2 (en) | 2010-06-16 | 2015-12-15 | Purdue Pharma, L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
WO2012007836A1 (en) | 2010-07-16 | 2012-01-19 | Purdue Pharma .Lp. | Pyridine compounds as sodium channel blockers |
US9056832B2 (en) | 2010-09-17 | 2015-06-16 | Purdue Pharma L.P. | Pyridine compounds and the users thereof |
AR083339A1 (en) | 2010-10-05 | 2013-02-21 | Purdue Pharma Lp | QUINAZOLINE COMPOUNDS AS BLOCKERS OF THE SODIUM CHANNELS |
AU2011346751A1 (en) | 2010-12-22 | 2013-05-02 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
US9163008B2 (en) | 2011-09-02 | 2015-10-20 | Purdue Pharma, L.P. | Pyrimidines as sodium channel blockers |
WO2013064884A1 (en) | 2011-10-31 | 2013-05-10 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
US9206127B2 (en) | 2012-03-16 | 2015-12-08 | Purdue Pharm, L.P. | Substituted pyridines as sodium channel blockers |
US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
US9637458B2 (en) | 2013-03-04 | 2017-05-02 | Jeffrey Lockman | Pyrimidine carboxamides as sodium channel blockers |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
CA2939549C (en) | 2013-03-15 | 2020-08-18 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
WO2015031036A1 (en) | 2013-08-26 | 2015-03-05 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
EP3083606B1 (en) | 2013-12-20 | 2020-10-28 | Purdue Pharma LP | Pyrimidines and use thereof |
CA2934473C (en) | 2013-12-23 | 2019-08-20 | Purdue Pharma L.P. | Indazoles and use thereof |
WO2015100174A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Ring-contracted morphinans and the use thereof |
CN106061944A (en) | 2014-01-24 | 2016-10-26 | 普渡制药公司 | Pyridines and pyrimidines and use thereof |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
-
2011
- 2011-09-16 US US13/821,732 patent/US9056832B2/en active Active
- 2011-09-16 WO PCT/IB2011/002172 patent/WO2012035421A2/en active Application Filing
- 2011-09-16 CA CA2811479A patent/CA2811479A1/en not_active Abandoned
- 2011-09-16 MX MX2013003101A patent/MX2013003101A/en not_active Application Discontinuation
- 2011-09-16 KR KR1020137009767A patent/KR20130056345A/en not_active Application Discontinuation
- 2011-09-16 JP JP2013528783A patent/JP2013538227A/en active Pending
- 2011-09-16 EP EP11776851.5A patent/EP2616441B1/en active Active
- 2011-09-16 BR BR112013006272A patent/BR112013006272A2/en not_active IP Right Cessation
- 2011-09-16 AU AU2011303597A patent/AU2011303597A1/en not_active Abandoned
- 2011-09-16 CN CN2011800446318A patent/CN103153955A/en active Pending
- 2011-09-16 AR ARP110103396A patent/AR083023A1/en unknown
- 2011-09-16 EP EP19189601.8A patent/EP3590925B1/en active Active
-
2013
- 2013-03-12 IL IL225185A patent/IL225185A0/en unknown
-
2015
- 2015-05-28 US US14/724,494 patent/US9611222B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136839A (en) | 1995-06-12 | 2000-10-24 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
Non-Patent Citations (53)
Title |
---|
"A Textbook of Drug Design and Development", 1991, HARWOOD ACADEMIC PUBLISHERS |
"Design of Prodrugs", 1985, ELSEVIER |
"Methods in Enzymology", vol. 112, 1985, ACADEMIC PRESS, article "Drug and Enzyme Targeting, Part A" |
A.L. BINGHAM ET AL., CHEM. COMMUN., 2001, pages 603 - 604 |
ANGER ET AL., J. MED. CHEM., vol. 44, 2001, pages 115 - 137 |
BAKER ET AL., TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 22, 2001, pages 27 - 31 |
BARTHO ET AL., NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOL., vol. 342, 1990, pages 666 - 670 |
BENJAMIN, J. BIOMOL. SCREEN, vol. 10, no. 4, 2005, pages 365 - 373 |
BLACK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 11598 - 115602 |
BROWER, NATURE BIOTECHNOLOGY, vol. 18, 2000, pages 387 - 391 |
BROWN ET AL., BRITISH J. PHARMACOL., vol. 115, 1995, pages 1425 - 1432 |
BUNDGAARD ET AL., ADV. DRUG DELIVERY REVS., vol. 8, 1992, pages 1 - 38 |
BUNDGAARD ET AL., J. PHARMACEUT. SCI., vol. 77, 1988, pages 285 |
BUNDGAARD: "Design and Application of Prodrugs", pages: 113 - 191 |
CANNON, KIDNEY INT., vol. 57, 2000, pages 772 - 779 |
CATTERALL, TRENDS PHARMACOL. SCI., vol. 8, 1987, pages 57 - 65 |
CHAHINE ET AL., CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, vol. 7, 2008, pages 144 - 158 |
CLARE ET AL., DRUG DISCOVERY TODAY, vol. 5, 2000, pages 506 - 510 |
CUMMINS ET AL., J. NEUROSCI., vol. 18, no. 23, 1998, pages 9607 - 9619 |
DONALDSON, LARYNGOL. OTOL., vol. 95, 1981, pages 947 - 951 |
E.C. VAN TONDER ET AL., AAPS PHARM. SCI. TECH., vol. 5, no. 1, 2004 |
FILER: "Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A", vol. 1, 1987 |
GLEN R. HANSON: "Remington: The Science and Practice of Pharmacy", vol. II, 1995, article "Analgesic, Antipyretic and Anti Inflammatory Drugs", pages: 1196 - 1221 |
GRAHAM ET AL., J. PHARMACOL. EXP. THER., vol. 269, 1994, pages 854 - 859 |
HAROOTUNIAN ET AL., J. BIOL. CHEM., vol. 264, no. 32, 1989, pages 19458 - 19467 |
HUBNER ET AL., HUM. MOL. GENET., vol. 11, 2002, pages 2435 - 2445 |
HUNSKAAR ET AL., J. NEUROSCI. METHODS, vol. 14, 1985, pages 69 - 76 |
ILYIN ET AL., BR. J PHARMACOL., vol. 144, 2005, pages 801 - 812 |
J. ORG. CHEM., vol. 63, 1998, pages 1740 - 1741 |
KAKEYA ET AL., CHEM. PHARM. BULL, vol. 32, 1984, pages 692 |
KIM ET AL., PAIN, vol. 50, no. 3, 1992, pages 355 - 363 |
KYLE, ILYIN, J. MED. CHEM., vol. 50, 2007, pages 2583 - 2588 |
LAI ET AL., ANNU. REV. PHARMACOL. TOXICOL., vol. 44, 2004, pages 371 - 397 |
LAI ET AL., CURRENT OPINION IN NEUROBIOLOGY, vol. 13, 2003, pages 291 - 297 |
LAIRD ET AL., J. NEUROSCI., vol. 22, 2002, pages 8352 - 8356 |
LEVINE: "Textbook of Pain", 1994, article "Inflammatory Pain" |
LIU ET AL., AM. J. PHARMACOGENOMICS, vol. 3, 2003, pages 173 - 179 |
M. CAIRA, J. PHARMACEUT. SCI., vol. 93, no. 3, 2004, pages 601 - 611 |
MAJUMDAR, B. ET AL., CLIN. OTOLARYNGOL., vol. 8, 1983, pages 175 - 180 |
MEISLER, KEARNEY, J. CLIN. INVEST., vol. 115, 2005, pages 2010 - 2017 |
MOLLER, AM. J. OTOL., vol. 18, 1997, pages 577 - 585 |
NASSAR ET AL., PROC NATL. ACAD. SCI. USA, vol. 101, 2004, pages 12706 - 12711 |
NOBLE, PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 5755 - 5756 |
PAUL A. INSEL: "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 1996, article "Analgesic Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout", pages: 617 - 57 |
SELTZER ET AL., PAIN, vol. 43, 1990, pages 205 - 218 |
SIMPSON ET AL., TIP., vol. 20, 1999, pages 12 - 18 |
SRIVATSA ET AL., CURR. CARDIOL. REP., vol. 4, 2002, pages 401 - 410 |
STEIN, BIOCHEMISTRY & BEHAVIOR, vol. 31, 1988, pages 451 - 455 |
TAYLOR, MELDRUM, TRENDS PHARMACOL. SCI., vol. 16, 1995, pages 309 - 316 |
TOLEDO-ARAL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 1527 - 1532 |
TONNDORF, HEAR. RES., vol. 28, 1987, pages 271 - 275 |
WOOD ET AL., J. NEUROBIOL., vol. 61, 2004, pages 55 - 71 |
YOGEESWARI ET AL., CURR. DRUG TARGET, vol. 5, 2004, pages 589 - 602 |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8536186B2 (en) | 2008-08-04 | 2013-09-17 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US9145373B2 (en) | 2008-08-04 | 2015-09-29 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US8883785B2 (en) | 2010-01-25 | 2014-11-11 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US9765029B2 (en) | 2010-07-16 | 2017-09-19 | Purdue Pharma L.P. | Pyridine compounds as sodium channel blockers |
US9120752B2 (en) | 2010-07-16 | 2015-09-01 | Purdue Pharma, L.P. | Pyridine compounds as sodium channel blockers |
US9611222B2 (en) | 2010-09-17 | 2017-04-04 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
US9056832B2 (en) | 2010-09-17 | 2015-06-16 | Purdue Pharma L.P. | Pyridine compounds and the users thereof |
US9981918B2 (en) | 2011-08-30 | 2018-05-29 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US9428464B2 (en) | 2011-08-30 | 2016-08-30 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US9624194B2 (en) | 2011-10-31 | 2017-04-18 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
US9388137B2 (en) | 2011-10-31 | 2016-07-12 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
US9539253B2 (en) | 2011-11-15 | 2017-01-10 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
WO2013072758A1 (en) * | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
US9718780B2 (en) | 2012-03-16 | 2017-08-01 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
JP2016511270A (en) * | 2013-03-04 | 2016-04-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Pyrimidine carboxamides as sodium channel blockers |
US10196364B2 (en) | 2013-03-04 | 2019-02-05 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
AU2017203017B2 (en) * | 2013-03-04 | 2018-12-20 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
US10000475B2 (en) | 2013-03-04 | 2018-06-19 | Purdue Pharma L.P. | Triazine carboxamides as sodium channel blockers |
WO2014135955A1 (en) * | 2013-03-04 | 2014-09-12 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
EP3293184A1 (en) * | 2013-03-04 | 2018-03-14 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
AU2014224310B2 (en) * | 2013-03-04 | 2017-02-09 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
US9637458B2 (en) | 2013-03-04 | 2017-05-02 | Jeffrey Lockman | Pyrimidine carboxamides as sodium channel blockers |
JP2018012701A (en) * | 2013-03-15 | 2018-01-25 | パーデュー、ファーマ、リミテッド、パートナーシップ | Carboxamide derivatives and use thereof |
EP3666274A1 (en) * | 2013-03-15 | 2020-06-17 | Purdue Pharma LP | Carboxamide derivatives and use thereof |
AU2017204263B2 (en) * | 2013-03-15 | 2019-05-09 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
AU2014235063B2 (en) * | 2013-03-15 | 2017-05-04 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
JP2016512840A (en) * | 2013-03-15 | 2016-05-09 | パーデュー、ファーマ、リミテッド、パートナーシップ | Carboxamide derivatives and uses thereof |
WO2014151393A3 (en) * | 2013-03-15 | 2014-12-18 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
US10005768B2 (en) | 2013-03-15 | 2018-06-26 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
US9493449B2 (en) | 2013-03-15 | 2016-11-15 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
WO2014151393A2 (en) * | 2013-03-15 | 2014-09-25 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
US20170096421A1 (en) * | 2013-03-15 | 2017-04-06 | Purdue Pharma L.P. | Carboxamide Derivatives and Use Thereof |
EP2968307A4 (en) * | 2013-03-15 | 2017-01-04 | Purdue Pharma LP | Carboxamide derivatives and use thereof |
US9822097B2 (en) | 2013-06-27 | 2017-11-21 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9139561B2 (en) | 2013-06-27 | 2015-09-22 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US11964961B2 (en) | 2013-06-27 | 2024-04-23 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US11014909B2 (en) | 2013-06-27 | 2021-05-25 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9527831B2 (en) | 2013-06-27 | 2016-12-27 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US10696658B2 (en) | 2013-06-27 | 2020-06-30 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US10421744B2 (en) | 2013-06-27 | 2019-09-24 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US10093655B2 (en) | 2013-06-27 | 2018-10-09 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9107923B2 (en) | 2013-06-27 | 2015-08-18 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US11180502B2 (en) | 2013-08-26 | 2021-11-23 | Purdue Pharma L.P. | Azaspiro[4.5]decane derivatives and use thereof |
US9884865B2 (en) | 2013-08-26 | 2018-02-06 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
US9745287B2 (en) | 2013-12-20 | 2017-08-29 | Purdue Pharma L.P. | Pyrimidines and use thereof |
WO2015094443A1 (en) | 2013-12-20 | 2015-06-25 | Purdue Pharma L.P. | Pyrimidines and use thereof |
US9834543B2 (en) | 2013-12-23 | 2017-12-05 | Purdue Pharma L.P. | Indazoles and use thereof |
US10155752B2 (en) | 2013-12-23 | 2018-12-18 | Purdue Pharma L.P. | Indazoles and use thereof |
US9902726B2 (en) | 2013-12-30 | 2018-02-27 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
US10047075B2 (en) | 2014-01-24 | 2018-08-14 | Purdue Pharma L.P. | Pyridines and pyrimidines and use thereof |
WO2015112801A1 (en) | 2014-01-24 | 2015-07-30 | Purdue Pharma L.P. | Pyridines and pyrimidines and use thereof |
US10738026B2 (en) | 2014-02-12 | 2020-08-11 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
US11401258B2 (en) | 2014-02-12 | 2022-08-02 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
US9975854B2 (en) | 2014-05-06 | 2018-05-22 | Purdue Pharma L.P. | Benzomorphan analogs and use thereof |
US10131666B2 (en) | 2014-06-13 | 2018-11-20 | Purdue Pharma L.P. | Heterocyclic morphinan derivatives and use thereof |
US10202382B2 (en) | 2014-06-13 | 2019-02-12 | Purdue Pharma L.P. | Azamorphinan derivatives and use thereof |
US10258621B2 (en) | 2014-07-17 | 2019-04-16 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
US9763955B2 (en) | 2015-02-19 | 2017-09-19 | Purdue Pharma L.P. | Methods and compositions for decreasing gastric emptying |
US10143696B2 (en) | 2015-02-19 | 2018-12-04 | Purdue Pharma L.P. | Methods and compositions for decreasing gastric emptying |
WO2020161146A1 (en) * | 2019-02-07 | 2020-08-13 | Nouryon Chemicals International B.V. | Process for manufacturing alkyleneamine compounds |
Also Published As
Publication number | Publication date |
---|---|
AU2011303597A1 (en) | 2013-04-11 |
EP2616441A2 (en) | 2013-07-24 |
WO2012035421A3 (en) | 2012-09-07 |
AR083023A1 (en) | 2013-01-23 |
EP3590925B1 (en) | 2022-03-30 |
CA2811479A1 (en) | 2012-03-22 |
EP3590925A1 (en) | 2020-01-08 |
EP2616441B1 (en) | 2019-08-07 |
US9611222B2 (en) | 2017-04-04 |
CN103153955A (en) | 2013-06-12 |
MX2013003101A (en) | 2013-09-26 |
US20150259293A1 (en) | 2015-09-17 |
BR112013006272A2 (en) | 2019-09-24 |
KR20130056345A (en) | 2013-05-29 |
IL225185A0 (en) | 2013-06-27 |
US20130303526A1 (en) | 2013-11-14 |
US9056832B2 (en) | 2015-06-16 |
JP2013538227A (en) | 2013-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9611222B2 (en) | Pyridine compounds and the uses thereof | |
US10774050B2 (en) | Pyrimidines as sodium channel blockers | |
US9539253B2 (en) | Pyrimidine diol amides as sodium channel blockers | |
EP2655330B1 (en) | Substituted pyridines as sodium channel blockers | |
US9765029B2 (en) | Pyridine compounds as sodium channel blockers | |
WO2013136170A1 (en) | Substituted pyridines as sodium channel blockers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180044631.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11776851 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 225185 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2013528783 Country of ref document: JP Kind code of ref document: A Ref document number: 2811479 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/003101 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2011303597 Country of ref document: AU Date of ref document: 20110916 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011776851 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137009767 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13821732 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013006272 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013006272 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130315 |